EP0654865B1
(en)
*
|
1993-10-27 |
1998-08-05 |
Molex Incorporated |
Shunted electrical connector
|
US5641870A
(en)
*
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US20040121415A1
(en)
*
|
1996-12-10 |
2004-06-24 |
King David John |
Monovalent antibody fragments
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
AU760048B2
(en)
*
|
1998-05-06 |
2003-05-08 |
Genentech Inc. |
Protein purification by ion exchange chromatography
|
EP1308455B9
(en)
*
|
1998-05-06 |
2006-06-14 |
Genentech, Inc. |
A composition comprising anti-HER2 antibodies
|
AU2003200708B2
(en)
*
|
1998-05-06 |
2007-01-04 |
Genentech, Inc. |
Protein purification
|
CN101121021B
(zh)
|
1999-06-25 |
2011-12-07 |
杰南技术公司 |
人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗
|
DK2283866T3
(en)
|
1999-06-25 |
2015-05-18 |
Genentech Inc |
METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
|
JP2001066308A
(ja)
*
|
1999-07-29 |
2001-03-16 |
Gsf Forschungszentrum Fuer Umwelt & Gesundheit Gmbh |
IgG抗体の不可逆的損傷の検出
|
US7074983B2
(en)
*
|
1999-11-19 |
2006-07-11 |
Kirin Beer Kabushiki Kaisha |
Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
|
US7414170B2
(en)
*
|
1999-11-19 |
2008-08-19 |
Kirin Beer Kabushiki Kaisha |
Transgenic bovines capable of human antibody production
|
US7820878B2
(en)
*
|
1999-11-19 |
2010-10-26 |
Kyowa Hakko Kirin Co., Ltd. |
Production of ungulates, preferably bovines that produce human immunoglobulins
|
WO2001035735A1
(en)
*
|
1999-11-19 |
2001-05-25 |
Hematech, Llc |
Production of ungulates, preferably bovines that produce human immunoglobulins
|
CA2402417A1
(en)
*
|
2000-03-02 |
2001-09-07 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of separating and purifying protein
|
US20030023043A1
(en)
*
|
2000-03-02 |
2003-01-30 |
Kazuhisa Uchida |
Method of separating and purifying protein
|
HUP0300369A2
(hu)
|
2000-04-11 |
2003-06-28 |
Genentech, Inc. |
Többértékű antitestek és alkalmazásuk
|
JP2004512262A
(ja)
|
2000-06-20 |
2004-04-22 |
アイデック ファーマスーティカルズ コーポレイション |
非放射性抗cd20抗体/放射標識抗cd22抗体の組合せ
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
JPWO2002030954A1
(ja)
*
|
2000-10-06 |
2004-02-19 |
協和醗酵工業株式会社 |
抗体を精製する方法
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
PT1324776E
(pt)
|
2000-10-12 |
2009-12-23 |
Genentech Inc |
Formulações de proteína concentradas de viscosidade reduzida
|
US6979556B2
(en)
*
|
2000-12-14 |
2005-12-27 |
Genentech, Inc. |
Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
KR100607612B1
(ko)
|
2001-06-20 |
2006-08-02 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
CN100513414C
(zh)
*
|
2001-08-27 |
2009-07-15 |
杰南技术公司 |
进行抗体表达和装配的系统
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
EP1487877B1
(en)
|
2001-09-18 |
2010-10-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis of tumors
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
KR20070087247A
(ko)
|
2002-01-02 |
2007-08-27 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
EP2289942B1
(en)
|
2002-04-10 |
2013-07-31 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
EP1571968A4
(en)
|
2002-04-16 |
2007-10-17 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
NZ537328A
(en)
*
|
2002-05-31 |
2008-04-30 |
Genetic Technologies Ltd |
Maternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
PL214010B1
(pl)
|
2002-07-15 |
2013-06-28 |
Genentech Inc |
Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala
|
JP2006512901A
(ja)
*
|
2002-08-29 |
2006-04-20 |
ジェネンテック・インコーポレーテッド |
Achaete−Scute様−2ポリペプチドとそのコード化核酸並びに腫瘍の診断と治療のための方法
|
SI1539798T1
(sl)
*
|
2002-09-06 |
2011-03-31 |
Genentech Inc |
Postopek za proteinsko ekstrakcijo
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
AU2003286493A1
(en)
*
|
2002-10-18 |
2004-05-04 |
Abgenix, Inc. |
System and method for cleaving antibodies
|
KR20050093761A
(ko)
*
|
2002-11-08 |
2005-09-23 |
헤마테크, 엘엘씨 |
프리온 단백질 활성이 감소된 트랜스제닉 유제동물 및 그의용도
|
CA2511946A1
(en)
|
2003-01-09 |
2004-10-28 |
Genentech, Inc. |
Purification of polypeptides
|
EP1599608A4
(en)
*
|
2003-03-05 |
2007-07-18 |
Genetic Technologies Ltd |
Identification of fetal DNA and fetal cell marker in maternal plasma or serum
|
EP1614693A4
(en)
*
|
2003-03-31 |
2006-07-19 |
Kirin Brewery |
PURIFICATION OF A HUMAN MONOCLONAL ANTIBODY AND A HUMAN POLYCLONAL ANTIBODY
|
ZA200507757B
(en)
|
2003-04-04 |
2007-01-31 |
Genentech Inc |
High concentration antibody and protein formulations
|
CA2519870A1
(en)
|
2003-04-09 |
2004-10-28 |
Genentech, Inc. |
Use of rituximab intravenous compositions to treat rheumatoid arthritis
|
EP1629014A2
(en)
*
|
2003-05-30 |
2006-03-01 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
ZA200509059B
(en)
|
2003-05-30 |
2007-01-31 |
Genentech Inc |
Treatment with anti-VEGF antibodies
|
CA2526402A1
(en)
|
2003-06-05 |
2005-01-20 |
Genentech, Inc. |
Blys antagonists and uses thereof
|
NZ544924A
(en)
*
|
2003-06-27 |
2009-03-31 |
Biogen Idec Inc |
Modified binding molecules comprising connecting peptides
|
KR100945327B1
(ko)
|
2003-07-08 |
2010-03-08 |
제넨테크, 인크. |
Il-17a/f 이종 폴리펩티드 및 그의 치료 용도
|
US20050165222A1
(en)
*
|
2003-10-15 |
2005-07-28 |
Applera Corporation |
Method of reducing leachate from protein a affinity media
|
WO2005042569A1
(en)
*
|
2003-10-24 |
2005-05-12 |
Amgen, Inc. |
Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
|
CN107213469A
(zh)
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
US20050214805A1
(en)
*
|
2003-11-10 |
2005-09-29 |
Q-Rna, Inc. |
Methods of detection employing immuno-Q-Amp technology
|
DK2295073T3
(da)
|
2003-11-17 |
2014-07-28 |
Genentech Inc |
Antistof mod cd22 til behandling af tumor af hæmatopoietisk oprindelse
|
US20060122783A1
(en)
*
|
2004-08-24 |
2006-06-08 |
Ishikawa Muriel Y |
System and method for heightening a humoral immune response
|
US20060047437A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Ishikawa Muriel Y |
System and method for heightening an immune response
|
US20060116824A1
(en)
*
|
2004-12-01 |
2006-06-01 |
Ishikawa Muriel Y |
System and method for modulating a humoral immune response
|
US20060095211A1
(en)
*
|
2003-12-05 |
2006-05-04 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for modulating a cell mediated immune response
|
US20060047434A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to improving an immune system
|
US20060182742A1
(en)
*
|
2004-08-24 |
2006-08-17 |
Ishikawa Muriel Y |
System and method for magnifying a humoral immune response
|
US20060047435A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to augmenting an immune system
|
US20060047436A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Ishikawa Muriel Y |
System and method for magnifying an immune response
|
US20060122784A1
(en)
*
|
2004-12-03 |
2006-06-08 |
Ishikawa Muriel Y |
System and method for augmenting a humoral immune response
|
US8021889B2
(en)
*
|
2004-01-20 |
2011-09-20 |
Pall Corporation |
Chromatographic material for the absorption of proteins at physiological ionic strength
|
US20050282233A1
(en)
*
|
2004-03-05 |
2005-12-22 |
Ludwig Institute For Cancer Research |
Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
|
NZ550217A
(en)
|
2004-03-31 |
2009-11-27 |
Genentech Inc |
Humanized anti-TGF-beta antibodies
|
BRPI0509412A
(pt)
*
|
2004-04-16 |
2007-09-04 |
Genentech Inc |
método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
|
KR20070012408A
(ko)
*
|
2004-04-16 |
2007-01-25 |
제넨테크, 인크. |
B 세포 고갈을 증대시키는 방법
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
AU2005237494B2
(en)
|
2004-04-22 |
2010-06-10 |
Kyowa Hakko Kirin Co., Ltd |
Transgenic animals and uses thereof
|
CN106075435A
(zh)
|
2004-06-04 |
2016-11-09 |
健泰科生物技术公司 |
用于治疗多发性硬化的方法
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
ZA200701183B
(en)
*
|
2004-07-20 |
2008-05-28 |
Genentech Inc |
Inhibitors of angiopoietin-like 4 protein, combinations, an their use
|
BRPI0513826A2
(pt)
|
2004-07-26 |
2010-06-22 |
Dow Global Technologies Inc |
processo para expressão de proteìna melhorada através de engenharia de cepa
|
US20070196362A1
(en)
*
|
2004-08-24 |
2007-08-23 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems to bolster an immune response
|
US20070265818A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for heightening cell-mediated immune response
|
US20070198196A1
(en)
*
|
2004-08-24 |
2007-08-23 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational systems and methods relating to ameliorating an immune system
|
US20070265819A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for improving cell-mediated immune response
|
US20070207492A1
(en)
*
|
2004-08-24 |
2007-09-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems to adjust a humoral immune response
|
US20070265787A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc,A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for magnifying cell-mediated immune response
|
US20070288173A1
(en)
*
|
2004-08-24 |
2007-12-13 |
Searete Llc, A Limited Liability Corporation Of The State Of Delware |
Computational methods and systems to reinforce a humoral immune response
|
US20070265788A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for augmenting cell-mediated immune response
|
US20070265817A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational systems and methods relating to fortifying an immune system
|
US20060047439A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for improving a humoral immune response
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
NZ590132A
(en)
*
|
2004-10-21 |
2012-03-30 |
Genentech Inc |
Dosage regime for treating intraocular neovascular diseases with VEGF
|
WO2006074399A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
CN101141981A
(zh)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
ES2440481T3
(es)
|
2005-02-23 |
2014-01-29 |
Genentech, Inc. |
Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
US8067182B2
(en)
|
2005-03-11 |
2011-11-29 |
Wyeth Llc |
Method of weak partitioning chromatography
|
US7939642B2
(en)
|
2005-04-09 |
2011-05-10 |
Fusion Antibodies Limited |
Antibody and uses thereof
|
CA2610709A1
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
CA2614436C
(en)
|
2005-07-07 |
2016-05-17 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
|
US8871720B2
(en)
*
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
EP1922410A2
(en)
|
2005-08-15 |
2008-05-21 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CN101370525B
(zh)
|
2005-08-19 |
2013-09-18 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
CA2623517A1
(en)
*
|
2005-09-23 |
2007-04-05 |
Walter Reed Army Institute Of Research (Wrair) |
Antibodies with simultaneous subsite specificities to protein and lipid epitopes
|
US7422899B2
(en)
*
|
2005-10-05 |
2008-09-09 |
Biogen Idec Ma Inc. |
Antibodies to the human prolactin receptor
|
PT2500360E
(pt)
|
2005-10-31 |
2015-10-15 |
Oncomed Pharm Inc |
Composições e métodos para diagnóstico e tratamento do cancro
|
WO2007056411A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Genentech, Inc. |
Method of producing pan-specific antibodies
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
CA2630432A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
ES2547689T3
(es)
|
2005-12-02 |
2015-10-08 |
Genentech, Inc. |
Composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con la señalización de citocinas que implican anticuerpos que se unen a IL-22 y a IL-22R
|
EP3309170B1
(en)
|
2005-12-15 |
2019-05-22 |
Genentech, Inc. |
Polyubiquitin antibodies
|
US7625759B2
(en)
*
|
2005-12-19 |
2009-12-01 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
AU2007248444B2
(en)
|
2006-01-05 |
2012-10-25 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
EP1988768A2
(en)
|
2006-02-17 |
2008-11-12 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
NZ571068A
(en)
|
2006-03-21 |
2012-06-29 |
Genentech Inc |
An antibody that can bind human alpha5beta1
|
EP2389950A1
(en)
|
2006-03-23 |
2011-11-30 |
Novartis AG |
Anti-tumor cell antigen antibody therapeutics
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
TW201333030A
(zh)
|
2006-04-05 |
2013-08-16 |
Abbott Biotech Ltd |
抗體之純化
|
DE102006017701A1
(de)
*
|
2006-04-15 |
2007-10-25 |
Degussa Gmbh |
Silicium-Titan-Mischoxidpulver, Dispersion hiervon und daraus hergestellter titanhaltiger Zeolith
|
AU2007297565A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
US20090142259A1
(en)
*
|
2006-05-12 |
2009-06-04 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
|
RS53168B
(en)
|
2006-05-30 |
2014-06-30 |
Genentech Inc. |
Antibodies and Immunoconjugates and Their Use
|
US8124743B2
(en)
*
|
2006-06-01 |
2012-02-28 |
President And Fellows Of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
US8874380B2
(en)
|
2010-12-09 |
2014-10-28 |
Rutgers, The State University Of New Jersey |
Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
|
DK2426150T3
(en)
|
2006-06-30 |
2018-01-22 |
Novo Nordisk As |
ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
|
JP2009543579A
(ja)
|
2006-07-19 |
2009-12-10 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
抗炎症反応のための標的としてのWSX−1/p28
|
WO2008021290A2
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
EP2423332A1
(en)
|
2006-08-25 |
2012-02-29 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
EP2059533B1
(en)
|
2006-08-30 |
2012-11-14 |
Genentech, Inc. |
Multispecific antibodies
|
SG10201510384UA
(en)
|
2006-09-13 |
2016-01-28 |
Abbvie Inc |
Cell culture improvements
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
MX2009003229A
(es)
|
2006-09-29 |
2009-06-18 |
Oncomed Pharm Inc |
Composiciones y metodos para diagnosticar y tratar cancer.
|
MX2009003774A
(es)
|
2006-10-12 |
2009-04-22 |
Genentech Inc |
Anticuerpos para linfotoxina-alfa.
|
PT2845866T
(pt)
|
2006-10-27 |
2017-08-09 |
Genentech Inc |
Anticorpos e imunoconjugados e utilizações dos mesmos
|
CN101534920B
(zh)
*
|
2006-11-01 |
2013-10-16 |
比奥根艾迪克Ma公司 |
通过低ph和二价阳离子分离生物大分子的方法
|
US20080108147A1
(en)
*
|
2006-11-03 |
2008-05-08 |
Tie Wei |
Reduction of non-specific binding in immunoassays
|
CA2670471A1
(en)
|
2006-11-22 |
2008-06-05 |
Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
CA2670696A1
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
US20090186034A1
(en)
*
|
2006-12-19 |
2009-07-23 |
Genetech, Inc. |
Gene expression markers for inflammatory bowel disease
|
WO2008079849A2
(en)
*
|
2006-12-22 |
2008-07-03 |
Genentech, Inc. |
Antibodies to insulin-like growth factor receptor
|
US20080171344A1
(en)
*
|
2006-12-22 |
2008-07-17 |
Kapsner Kenneth P |
Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
|
EP2120915B1
(en)
|
2007-01-22 |
2011-09-28 |
Genentech, Inc. |
Polyelectrolyte precipitation and purification of antibodies
|
US8148147B2
(en)
|
2007-01-24 |
2012-04-03 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
US20100119526A1
(en)
*
|
2007-01-26 |
2010-05-13 |
Bioinvent International Ab |
DLL4 Signaling Inhibitors and Uses Thereof
|
KR20090114443A
(ko)
|
2007-02-09 |
2009-11-03 |
제넨테크, 인크. |
항-Robo4 항체 및 그의 용도
|
US20080214795A1
(en)
*
|
2007-02-14 |
2008-09-04 |
Amgen Inc. |
Method of isolating antibodies by precipitation
|
CA2676790A1
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
CL2008000614A1
(es)
*
|
2007-03-02 |
2008-09-05 |
Genentech Inc F Hoffmann La Ro |
Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her.
|
KR101576219B1
(ko)
|
2007-03-14 |
2015-12-10 |
다케다 백신즈 인코포레이티드 |
바이러스 유사 입자 정제
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
EP2142651B1
(en)
|
2007-04-27 |
2013-05-22 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
EP2650018A3
(en)
|
2007-05-14 |
2014-09-03 |
The University of Chicago |
Antibody-LIGHT fusion products for cancer therapeutics
|
SI2171090T1
(sl)
|
2007-06-08 |
2013-07-31 |
Genentech, Inc. |
Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
|
HUE027154T2
(en)
|
2007-07-02 |
2016-08-29 |
Oncomed Pharm Inc |
Preparations and procedures for the treatment and diagnosis of cancer
|
AU2008276128B2
(en)
|
2007-07-16 |
2013-10-10 |
Genentech, Inc. |
Humanized anti-CD79b antibodies and immunoconjugates and methods of use
|
ES2381788T3
(es)
|
2007-07-16 |
2012-05-31 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
EP2069401A4
(en)
*
|
2007-07-31 |
2011-02-23 |
Medimmune Llc |
MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
|
EP3492488A1
(en)
|
2007-08-22 |
2019-06-05 |
The Regents of The University of California |
Activatable binding polypeptides and methods of identification and use thereof
|
US8709731B2
(en)
|
2007-08-24 |
2014-04-29 |
Oncotherapy Science, Inc. |
DKK1 oncogene as therapeutic target for cancer and a diagnosing marker
|
RU2010111120A
(ru)
|
2007-08-24 |
2011-09-27 |
Онкотерапи Сайенс, Инк. (Jp) |
Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого
|
CN101855346A
(zh)
|
2007-08-24 |
2010-10-06 |
肿瘤疗法科学股份有限公司 |
Pkib和naaladl2用作前列腺癌治疗和诊断的靶基因
|
JP5592792B2
(ja)
|
2007-09-26 |
2014-09-17 |
ユセベ ファルマ ソシエテ アノニム |
二重特異性抗体の融合体
|
DK2202245T3
(en)
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
CA2699601A1
(en)
|
2007-10-02 |
2009-04-09 |
Genentech, Inc. |
Nlrr-1 antagonists and uses thereof
|
WO2009045897A1
(en)
*
|
2007-10-03 |
2009-04-09 |
Dyax Corp. |
Systems and methods for purifying proteins
|
WO2009052293A1
(en)
|
2007-10-16 |
2009-04-23 |
Zymogenetics, Inc. |
Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
|
US20090148435A1
(en)
|
2007-10-30 |
2009-06-11 |
Genentech, Inc. |
Antibody purification by cation exchange chromatography
|
EP2209491B1
(en)
|
2007-11-02 |
2015-10-28 |
Novartis AG |
Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
|
ES2662845T3
(es)
|
2007-11-07 |
2018-04-10 |
Genentech, Inc. |
IL-22 para su uso en el tratamiento de trastornos microbianos
|
DK2220116T3
(da)
|
2007-11-12 |
2012-11-26 |
Theraclone Sciences Inc |
Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
MX2010005893A
(es)
|
2007-11-29 |
2011-03-04 |
Genentech Inc Star |
Marcadores de expresion genica para enfermedad inflamatoria de intestino.
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
GB0723797D0
(en)
*
|
2007-12-05 |
2008-01-16 |
Immunosolv Ltd |
Method
|
RU2563343C2
(ru)
|
2007-12-14 |
2015-09-20 |
Ново Нордиск А/С |
Антитела к человеческому nkg2d и их применения
|
WO2009117035A1
(en)
|
2007-12-19 |
2009-09-24 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
AR070141A1
(es)
*
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
BRPI0908508A2
(pt)
|
2008-01-24 |
2016-03-22 |
Novo Nordisk As |
anticorpo monoclonal nkg2a anti-humano humanizado
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
IL287292B
(en)
|
2008-01-31 |
2022-09-01 |
Genentech Inc |
and fusion antibody-drug-cd79b engineered antibodies cysteine-
|
KR20100128291A
(ko)
|
2008-02-14 |
2010-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
Egfr에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
|
DK2602623T3
(en)
|
2008-02-25 |
2015-11-09 |
Nestec Sa |
METHOD OF DETECTING INTRACELLULAR TRUNCTED RECEPTORS
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
WO2009114560A2
(en)
|
2008-03-10 |
2009-09-17 |
Spaltudaq Corporation |
Compositions and methods for the therapy and diagnosis of cytomegalovirus
|
US10000568B2
(en)
|
2008-04-10 |
2018-06-19 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting EGFR in cancer
|
CN102065870B
(zh)
*
|
2008-04-16 |
2014-11-19 |
比奥根艾迪克Ma公司 |
使用聚亚烷基二醇和过渡金属分离生物大分子的方法
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
CA2723707C
(en)
|
2008-05-09 |
2016-08-23 |
Akonni Biosystems |
Microarray system
|
US8680025B2
(en)
*
|
2008-05-09 |
2014-03-25 |
Akonni Biosystems, Inc. |
Microarray system
|
US8680026B2
(en)
|
2008-05-09 |
2014-03-25 |
Akonni Biosystems, Inc. |
Flow cell device
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
PE20091931A1
(es)
|
2008-05-22 |
2009-12-31 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
EP2297209A4
(en)
*
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
CA2729839A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Diane Retallack |
High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein
|
CN102149825B
(zh)
*
|
2008-07-08 |
2015-07-22 |
Abbvie公司 |
前列腺素e2双重可变结构域免疫球蛋白及其用途
|
MY155603A
(en)
|
2008-07-08 |
2015-11-13 |
Oncomed Pharm Inc |
Notch-binding agents and antagonists and methods of use thereof
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
EP2328616B1
(en)
|
2008-08-05 |
2015-04-29 |
Novartis AG |
Compositions and methods for antibodies against complement protein c5
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
PE20150222A1
(es)
|
2008-09-03 |
2015-03-02 |
Genentech Inc |
Anticuerpos multiespecificos
|
EP2334323A2
(en)
|
2008-09-10 |
2011-06-22 |
F. Hoffmann-La Roche AG |
Compositions and methods for the prevention of oxidative degradation of proteins
|
TW201014605A
(en)
*
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
WO2010035012A1
(en)
*
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
GB0818228D0
(en)
|
2008-10-06 |
2008-11-12 |
Avecia Biolog Ltd |
Purification process
|
RU2536937C2
(ru)
|
2008-10-14 |
2014-12-27 |
Дженентек, Инк. |
Варианты иммуноглобулина и их применения
|
EP2346897A2
(en)
|
2008-10-20 |
2011-07-27 |
Abbott Laboratories |
Viral inactivation during purification of antibodies
|
TW201024318A
(en)
*
|
2008-10-20 |
2010-07-01 |
Abbott Lab |
Isolation and purification of antibodies using protein A affinity chromatography
|
RS55784B1
(sr)
|
2008-11-11 |
2017-07-31 |
Univ Michigan Regents |
Anti-cxcr1 kompozicije i postupci
|
EP2346529B1
(en)
*
|
2008-11-12 |
2016-02-10 |
Theraclone Sciences, Inc. |
Human m2e peptide immunogens
|
WO2010056981A2
(en)
|
2008-11-13 |
2010-05-20 |
Massachusetts General Hospital |
Methods and compositions for regulating iron homeostasis by modulation bmp-6
|
CA2744158A1
(en)
|
2008-11-22 |
2010-05-27 |
Genentech, Inc. |
Anti-angiogenesis therapy for the treatment of breast cancer
|
WO2010062858A1
(en)
*
|
2008-11-26 |
2010-06-03 |
Allergan, Inc. |
Il-17 antibody inhibitor for treating dry eye
|
US8211434B2
(en)
|
2008-11-26 |
2012-07-03 |
Allergan, Inc. |
KLK-13 antibody inhibitor for treating dry eye
|
RU2011127198A
(ru)
*
|
2008-12-04 |
2013-01-10 |
Эбботт Лэборетриз |
Иммуноглобулины с двойными вариабельными доменами и их применение
|
HRP20240240T1
(hr)
|
2008-12-09 |
2024-04-26 |
F. Hoffmann - La Roche Ag |
Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
|
EP2376117A1
(en)
|
2008-12-17 |
2011-10-19 |
Genentech, Inc. |
Hepatitis c virus combination therapy
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
BRPI0918204A2
(pt)
|
2008-12-23 |
2015-12-08 |
Genentech Inc |
igv variante composição farmaceutica e kit
|
US20110142836A1
(en)
*
|
2009-01-02 |
2011-06-16 |
Olav Mella |
B-cell depleting agents for the treatment of chronic fatigue syndrome
|
AU2010203353B2
(en)
|
2009-01-12 |
2016-06-16 |
Cytomx Therapeutics, Inc |
Modified antibody compositions, methods of making and using thereof
|
GB0902916D0
(en)
|
2009-02-20 |
2009-04-08 |
Fusion Antibodies Ltd |
Antibody therapy
|
KR20110122859A
(ko)
*
|
2009-02-23 |
2011-11-11 |
그렌마크 파머수티칼스 에스. 아. |
Cd19에 결합하는 인간화된 항체 및 그것의 용도
|
EP2398494A4
(en)
|
2009-02-23 |
2015-10-28 |
Cytomx Therapeutics Inc |
Proproteins and their methods of use
|
GB0903168D0
(en)
|
2009-02-25 |
2009-04-08 |
Fusion Antibodies Ltd |
Diagnostic method and kit
|
PE20160653A1
(es)
|
2009-03-05 |
2016-07-24 |
Abbvie Inc |
Proteinas de union a il-17
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
CN102356092B
(zh)
|
2009-03-20 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
TWI504409B
(zh)
|
2009-03-25 |
2015-10-21 |
Genentech Inc |
新穎抗-α5β1抗體及其用途
|
CN104788564A
(zh)
|
2009-03-25 |
2015-07-22 |
健泰科生物技术公司 |
抗-fgfr3抗体及其使用方法
|
JP5681166B2
(ja)
|
2009-03-31 |
2015-03-04 |
スリーエム イノベイティブ プロパティズ カンパニー |
疎水性モノマー、疎水的に誘導体化された支持体、並びにその製造及び使用方法
|
AR075998A1
(es)
|
2009-04-01 |
2011-05-11 |
Genentech Inc |
Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
|
CA2757382A1
(en)
|
2009-04-01 |
2010-10-21 |
Kristi Elkins |
Anti-fcrh5 antibodies and immunoconjugates
|
CN102369215B
(zh)
|
2009-04-02 |
2015-01-21 |
罗切格利卡特公司 |
包含全长抗体和单链Fab片段的多特异性抗体
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
WO2010115932A1
(en)
|
2009-04-08 |
2010-10-14 |
Novartis Ag |
Combination for the treatment of bone loss
|
SG175282A1
(en)
|
2009-04-21 |
2011-11-28 |
Genetic Technologies Ltd |
Methods for obtaining fetal genetic material
|
WO2010124113A1
(en)
|
2009-04-23 |
2010-10-28 |
Infinity Pharmaceuticals, Inc. |
Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
|
SG175305A1
(en)
*
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
CA2762302A1
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2010141630A1
(en)
|
2009-06-03 |
2010-12-09 |
University Of Southern California |
Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway
|
JP2012532873A
(ja)
|
2009-07-07 |
2012-12-20 |
ジェネンテック, インコーポレイテッド |
自己免疫性脱髄疾患の診断と治療
|
AU2010273319B2
(en)
|
2009-07-15 |
2015-01-22 |
Nestec S.A. |
Drug selection for gastric cancer therapy using antibody-based arrays
|
EP2456890A1
(en)
|
2009-07-20 |
2012-05-30 |
Genentech, Inc. |
Gene expression markers for crohn's disease
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
UY32808A
(es)
*
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
ES2513292T3
(es)
|
2009-07-31 |
2014-10-24 |
Genentech, Inc. |
Inhibición de metástasis tumoral usando anticuerpos anti-G-CSF
|
KR20190018041A
(ko)
|
2009-08-06 |
2019-02-20 |
제넨테크, 인크. |
단백질 정제 시의 바이러스 제거의 개선방법
|
US9133500B2
(en)
|
2009-08-10 |
2015-09-15 |
MorphoSys A6 |
Screening strategies for the identification of binders
|
US20110038871A1
(en)
|
2009-08-11 |
2011-02-17 |
Veena Viswanth |
Ccr2 inhibitors for treating conditions of the eye
|
RU2639288C2
(ru)
|
2009-08-11 |
2017-12-20 |
Дженентек, Инк. |
Получение белков в культуральных средах без глутамина
|
BR112012003346A2
(pt)
|
2009-08-15 |
2016-11-16 |
Genentech Inc |
metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
|
CA2952742A1
(en)
*
|
2009-08-29 |
2011-03-03 |
Abbvie Inc. |
Therapeutic dll4 binding proteins
|
TW201119673A
(en)
|
2009-09-01 |
2011-06-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
DK2473522T3
(en)
|
2009-09-02 |
2016-11-28 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
BR112012005893A2
(pt)
|
2009-09-16 |
2016-11-22 |
Genentech Inc |
hélice enrolada e/ou complexos de proteínas contendo conectores e usos dos mesmos
|
CA2772670A1
(en)
|
2009-09-17 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
US8470552B2
(en)
*
|
2009-10-12 |
2013-06-25 |
Keck Graduate Institute |
Strategy to reduce lactic acid production and control PH in animal cell culture
|
PE20121531A1
(es)
|
2009-10-15 |
2012-12-22 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual
|
HUE029661T2
(en)
|
2009-10-16 |
2017-03-28 |
Oncomed Pharm Inc |
A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
|
WO2011050069A1
(en)
|
2009-10-20 |
2011-04-28 |
Prometheus Laboratories Inc. |
Proximity-mediated assays for detecting oncogenic fusion proteins
|
US8435511B2
(en)
|
2009-10-22 |
2013-05-07 |
Genentech, Inc. |
Anti-hepsin antibodies and methods using same
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
RU2012122240A
(ru)
|
2009-10-30 |
2013-12-10 |
Эбботт Лэборетриз |
Конструкции sorf и экспрессия нескольких генов
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
CA2780221A1
(en)
|
2009-11-04 |
2011-05-12 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
US8361744B2
(en)
*
|
2009-11-05 |
2013-01-29 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
WO2011066503A2
(en)
|
2009-11-30 |
2011-06-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
TWI623323B
(zh)
|
2009-12-21 |
2018-05-11 |
建南德克公司 |
抗體調配物
|
JP5852010B2
(ja)
|
2009-12-23 |
2016-02-03 |
ジェネンテック, インコーポレイテッド |
抗Bv8抗体およびその使用
|
GB0922553D0
(en)
|
2009-12-23 |
2010-02-10 |
Fusion Antibodies Ltd |
Prognostic marker
|
ES2701626T3
(es)
|
2009-12-28 |
2019-02-25 |
Oncotherapy Science Inc |
Anticuerpos anti-CDH3 y sus usos
|
AU2011205316B2
(en)
|
2010-01-13 |
2015-05-28 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
ES2551871T3
(es)
|
2010-01-29 |
2015-11-24 |
Morphosys Ag |
Genotecas combinatorias de anticuerpos de roedor
|
EP2534257B1
(en)
|
2010-02-12 |
2017-09-27 |
Oncomed Pharmaceuticals, Inc. |
Methods for identifying and isolating cells expressing a polypeptide
|
JP2013520442A
(ja)
|
2010-02-23 |
2013-06-06 |
ジェネンテック, インコーポレイテッド |
卵巣癌の治療のための抗血管新生治療
|
KR20130004579A
(ko)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
NZ724971A
(en)
|
2010-02-24 |
2019-06-28 |
Immunogen Inc |
Folate receptor 1 antibodies and immunoconjugates and uses thereof
|
BR112012021941A2
(pt)
|
2010-03-02 |
2022-02-01 |
Abbvie Inc |
Proteínas terapêuticas de ligação a dll4
|
MY173839A
(en)
|
2010-03-12 |
2020-02-24 |
Debiopharm Int Sa |
Cd37-binding molecules and immunoconjugates thereof
|
EP2550018B1
(en)
|
2010-03-22 |
2019-02-27 |
F.Hoffmann-La Roche Ag |
Compositions and methods useful for stabilizing protein-containing formulations
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
BR112012026098A2
(pt)
|
2010-04-16 |
2016-11-22 |
Novartis Ag |
métodos e composições para melhorar a osseointegração de implante.
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
CA2796633C
(en)
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
MX342239B
(es)
|
2010-05-03 |
2016-09-21 |
Genentech Inc * |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
AU2011249783B9
(en)
|
2010-05-06 |
2014-11-06 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies
|
AU2011249782B2
(en)
|
2010-05-06 |
2014-10-02 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
|
EP2975409B1
(en)
|
2010-05-10 |
2018-10-31 |
Academia Sinica |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
EP2571532B1
(en)
|
2010-05-14 |
2017-05-03 |
Abbvie Inc. |
Il-1 binding proteins
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
MX370828B
(es)
|
2010-05-25 |
2020-01-08 |
Genentech Inc |
Métodos de purificación de polipéptidos.
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
RU2613886C2
(ru)
|
2010-06-03 |
2017-03-21 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
|
WO2011156369A2
(en)
*
|
2010-06-07 |
2011-12-15 |
Dr. Reddy's Laboratories Ltd. |
Purification of modified cytokines
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
CN103068367B
(zh)
|
2010-06-24 |
2016-09-07 |
弗·哈夫曼-拉罗切有限公司 |
用于稳定含有蛋白质的制剂的含有烷基糖苷的组合物和方法
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2012012750A1
(en)
|
2010-07-23 |
2012-01-26 |
Trustees Of Boston University |
ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
|
AU2011285852B2
(en)
|
2010-08-03 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
AU2011289275A1
(en)
|
2010-08-12 |
2013-02-21 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Fc領域を含むモノマーポリペプチド及び使用方法
|
JP2013537539A
(ja)
|
2010-08-13 |
2013-10-03 |
ジェネンテック, インコーポレイテッド |
疾患の治療のためのIL−1β及びIL−18に対する抗体
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
US9291606B2
(en)
|
2010-08-20 |
2016-03-22 |
General Electric Company |
Quality control devices and methods for radiopharmaceuticals
|
PT2606070T
(pt)
|
2010-08-20 |
2017-03-31 |
Novartis Ag |
Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
|
CA2807278A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann - La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
KR20130139884A
(ko)
|
2010-08-26 |
2013-12-23 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
EP3556396B1
(en)
|
2010-08-31 |
2022-04-20 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
WO2012030512A1
(en)
*
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
WO2012032043A1
(en)
|
2010-09-07 |
2012-03-15 |
Areva Med Llc |
212 pb imaging
|
WO2012033953A1
(en)
|
2010-09-08 |
2012-03-15 |
Halozyme, Inc. |
Methods for assessing and identifying or evolving conditionally active therapeutic proteins
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
EP3223014B1
(en)
*
|
2010-09-24 |
2018-12-05 |
Full Spectrum Genetics, Inc. |
Method of analyzing binding interactions
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
AR083546A1
(es)
|
2010-10-25 |
2013-03-06 |
Genentech Inc |
Tratamiento de inflamacion gastrointestinal, soriasis y asma
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
WO2012075333A2
(en)
|
2010-12-02 |
2012-06-07 |
Prometheus Laboratories Inc. |
Her2delta16 peptides
|
US8853365B2
(en)
|
2010-12-21 |
2014-10-07 |
Abbvie Inc. |
Dual variable domain immunnoglobulins and uses thereof
|
KR20130133212A
(ko)
|
2010-12-23 |
2013-12-06 |
인터셀 오스트리아 아게 |
입원 및 다른 환자에서 OprF/I 물질 및 이의 용도
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
CA2822283A1
(en)
|
2010-12-23 |
2012-06-28 |
Nestec S.A. |
Drug selection for malignant cancer therapy using antibody-based arrays
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
US20150018408A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
EP2663333B8
(en)
|
2011-01-10 |
2020-06-17 |
The Regents Of The University Of Michigan |
Stem cell factor inhibitor
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
BR112013019499B1
(pt)
|
2011-02-04 |
2023-01-10 |
Genentech, Inc. |
Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
|
TW201245223A
(en)
|
2011-02-14 |
2012-11-16 |
Theraclone Sciences Inc |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
EP2683290B1
(en)
|
2011-03-07 |
2018-11-07 |
F.Hoffmann-La Roche Ag |
Methods for in vivo testing of therapeutic antibodies
|
EP2683413A1
(en)
|
2011-03-07 |
2014-01-15 |
F.Hoffmann-La Roche Ag |
In vivo selection of therapeutically active antibodies
|
CA2829606C
(en)
|
2011-03-09 |
2020-06-02 |
Cell Signaling Technology, Inc. |
Methods and reagents for creating monoclonal antibodies
|
JP2014509591A
(ja)
|
2011-03-15 |
2014-04-21 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
BR112013024521A2
(pt)
|
2011-03-25 |
2019-09-24 |
Genentech Inc |
métodos de purificação de proteínas
|
RU2016127812A
(ru)
|
2011-03-31 |
2018-12-06 |
Дженентек, Инк. |
Способы введения антагонистов интегрина бета7
|
CA2834288A1
(en)
|
2011-04-25 |
2012-11-01 |
Advanced Bioscience Laboratories, Inc. |
Truncated hiv envelope proteins (env), methods and compositions related thereto
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
JP2014515759A
(ja)
|
2011-04-29 |
2014-07-03 |
ノバルティス アーゲー |
扁平上皮がんを治療する方法関連出願
|
JP2014518624A
(ja)
|
2011-05-12 |
2014-08-07 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
ニューログラニン診断キットのためのアッセイ試薬
|
IL276182B
(en)
|
2011-05-17 |
2022-09-01 |
Univ Rockefeller |
Neutralizing antibodies against the human immunodeficiency virus and methods of using them
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
EP2540828A1
(en)
|
2011-06-30 |
2013-01-02 |
Gene Signal International SA |
Composition comprising inhibitors of IRS-1 and of VEGF
|
WO2013001080A1
(en)
|
2011-06-30 |
2013-01-03 |
Gene Signal International Sa |
Composition comprising inhibitors of irs-1 and of vegf
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
LT2731677T
(lt)
|
2011-07-11 |
2018-07-10 |
Glenmark Pharmaceuticals S.A. |
Antikūnai, kurie prisiriša prie ox40, ir jų panaudojimas
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
US9493549B2
(en)
|
2011-07-25 |
2016-11-15 |
The Rockefeller University |
Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
|
US9890207B2
(en)
|
2011-07-25 |
2018-02-13 |
California Institute Of Technology |
Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
|
KR20190133790A
(ko)
|
2011-08-01 |
2019-12-03 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
|
EP2744825A1
(en)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Inhibition of angiogenesis in refractory tumors
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
WO2013033623A1
(en)
|
2011-09-02 |
2013-03-07 |
Nestec S.A. |
Profiling of signal pathway proteins to determine therapeutic efficacy
|
EA029958B1
(ru)
|
2011-09-23 |
2018-06-29 |
Онкомед Фармасьютикалс, Инк. |
Антитела, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение
|
US9575073B2
(en)
|
2011-10-10 |
2017-02-21 |
Rutgers, The State University Of New Jersey |
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
|
SI2766397T1
(sl)
|
2011-10-11 |
2018-09-28 |
F. Hoffmann-La Roche Ag |
Izboljšano sestavljanje bispecifičnih protiteles
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
EP2766037A4
(en)
|
2011-10-12 |
2015-08-05 |
Scripps Research Inst |
HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
|
ES2769786T3
(es)
|
2011-10-14 |
2020-06-29 |
Recordati Ag |
Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
|
EP2581388A1
(en)
|
2011-10-14 |
2013-04-17 |
Centre National de la Recherche Scientifique (CNRS) |
Anti-sPLA2-V antibodies and uses thereof
|
RU2014121043A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
|
RU2014120981A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Иммунные связывающие агенты против склеростина
|
DK2773438T4
(da)
|
2011-11-02 |
2022-01-03 |
Hoffmann La Roche |
Overladnings- og elueringskromatografi
|
DK2797957T3
(da)
|
2011-11-23 |
2019-09-23 |
Medimmune Llc |
Bindingsmolekyler specifikke for her3 og anvendelser deraf
|
DK2785375T3
(da)
|
2011-11-28 |
2020-10-12 |
Merck Patent Gmbh |
Anti-pd-l1-antistoffer og anvendelser deraf
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
BR112014013568A8
(pt)
|
2011-12-05 |
2017-06-13 |
Novartis Ag |
anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
|
MX362521B
(es)
|
2011-12-05 |
2019-01-22 |
Novartis Ag |
Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3).
|
EP2602265A1
(en)
|
2011-12-07 |
2013-06-12 |
Centre National de la Recherche Scientifique (CNRS) |
Antibodies anti-sPLA2-X and uses thereof
|
AU2012352454A1
(en)
|
2011-12-15 |
2014-07-17 |
The University Of Chicago |
Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
|
WO2013093762A1
(en)
|
2011-12-21 |
2013-06-27 |
Novartis Ag |
Compositions and methods for antibodies targeting factor p
|
IL267585B
(en)
*
|
2011-12-22 |
2022-09-01 |
Genentech Inc |
Ion exchange membrane chromatography
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
AU2012362326A1
(en)
|
2011-12-30 |
2014-07-24 |
Abbvie Inc. |
Dual variable domain immunoglobulins against IL-13 and/or IL-17
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
EP2802603A4
(en)
|
2012-01-09 |
2015-11-04 |
Scripps Research Inst |
REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
US20130243750A1
(en)
|
2012-01-31 |
2013-09-19 |
Genentech, Inc. |
Anti-ige antibodies and methods using same
|
EP2812357B1
(en)
|
2012-02-10 |
2020-11-04 |
F.Hoffmann-La Roche Ag |
Single-chain antibodies and other heteromultimers
|
SG11201405553YA
(en)
|
2012-03-08 |
2014-11-27 |
Halozyme Inc |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
EP2641916A1
(en)
|
2012-03-23 |
2013-09-25 |
Centre National de la Recherche Scientifique (C.N.R.S) |
Novel antibodies anti-sPLA2-IIA and uses thereof
|
AU2013240261A1
(en)
|
2012-03-27 |
2014-09-18 |
Genentech, Inc. |
Diagnosis and treatments relating to HER3 inhibitors
|
EP2830659A1
(en)
|
2012-03-27 |
2015-02-04 |
Novartis AG |
Treatment of fibrosis
|
EP2833900B1
(en)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013176754A1
(en)
*
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
EP3556776A1
(en)
|
2012-05-31 |
2019-10-23 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists
|
ES2703540T3
(es)
|
2012-06-04 |
2019-03-11 |
Novartis Ag |
Métodos de marcación específicos del sitio y moléculas producidas de este modo
|
JP2015520182A
(ja)
|
2012-06-08 |
2015-07-16 |
グレンマーク ファーマシューティカルズ, エセ.アー. |
アミノ酸置換を有するヒト化抗TrkA抗体
|
WO2013192589A1
(en)
|
2012-06-21 |
2013-12-27 |
California Institute Of Technology |
Antibodies targeting hiv escape mutants
|
JOP20130186B1
(ar)
|
2012-06-22 |
2021-08-17 |
Takeda Vaccines Montana Inc |
تنقية الجزيئات الشبيهة بالفيروسات
|
CN104411718B
(zh)
|
2012-06-27 |
2018-04-24 |
弗·哈夫曼-拉罗切有限公司 |
用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
|
CN104395339A
(zh)
|
2012-06-27 |
2015-03-04 |
弗·哈夫曼-拉罗切有限公司 |
用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
WO2014022332A1
(en)
|
2012-07-31 |
2014-02-06 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
US9297806B2
(en)
|
2012-08-01 |
2016-03-29 |
The Johns Hopkins University |
5-hydroxymethylcytosine in human cancer
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
EP2885311B1
(en)
|
2012-08-18 |
2020-01-01 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
EP2888238A4
(en)
|
2012-08-21 |
2016-01-27 |
Academia Sinica |
BENZOCYCLO-OCTYNE COMPOUNDS AND USES THEREOF
|
ES2666000T3
(es)
|
2012-08-21 |
2018-04-30 |
Janssen Pharmaceutica, N.V. |
Anticuerpos para aripiprazol y uso de los mismos
|
JP6374387B2
(ja)
|
2012-08-21 |
2018-08-15 |
ヤンセン ファーマシューティカ エヌ.ベー. |
リスペリドンハプテンへの抗体及びその使用
|
US9465041B2
(en)
|
2012-08-21 |
2016-10-11 |
Janssen Pharmaceutica Nv |
Antibodies to paliperidone and use thereof
|
AU2013305904B2
(en)
|
2012-08-21 |
2017-08-17 |
Saladax Biomedical Inc. |
Antibodies to quetiapine haptens and use thereof
|
JP2015529199A
(ja)
|
2012-08-21 |
2015-10-05 |
オルソ−クリニカル ダイアグノスティクス,インコーポレイティド |
パリペリドンハプテンに対する抗体及びその使用
|
AU2013305907B2
(en)
|
2012-08-21 |
2018-01-18 |
Saladax Biomedical Inc. |
Antibodies to quetiapine and use thereof
|
JP6389176B2
(ja)
|
2012-08-21 |
2018-09-12 |
ヤンセン ファーマシューティカ エヌ.ベー. |
アリピプラゾールハプテンに対する抗体及びその使用
|
CN108484496B
(zh)
|
2012-08-21 |
2022-03-22 |
詹森药业有限公司 |
阿立哌唑半抗原及其在免疫测定中的应用
|
CA2882596C
(en)
|
2012-08-21 |
2019-05-14 |
Ortho-Clinical Diagnostics, Inc. |
Antibodies to olanzapine and use thereof
|
TR201816416T4
(tr)
|
2012-08-21 |
2018-11-21 |
Janssen Pharmaceutica Nv |
Risperidona yönelik antikorlar ve bunların kullanımı.
|
TR201910347T4
(tr)
|
2012-08-21 |
2019-07-22 |
Janssen Pharmaceutica Nv |
Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
|
RS60217B1
(sr)
|
2012-08-31 |
2020-06-30 |
Immunogen Inc |
Dijagnostički testovi i kompleti za detekciju folatnog receptora 1
|
BR112015004467A2
(pt)
|
2012-09-02 |
2017-03-21 |
Abbvie Inc |
método para controlar a heterogeneidade de proteínas
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
EP2892555B1
(en)
|
2012-09-10 |
2020-03-25 |
International Aids Vaccine Initiative |
Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
|
SI2908912T1
(sl)
|
2012-10-18 |
2021-03-31 |
The Rockefeller University |
Široko nevtralizirajoča protitelesa proti HIV
|
US9599620B2
(en)
|
2012-10-31 |
2017-03-21 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a DLL4 antagonist
|
AR093311A1
(es)
|
2012-11-01 |
2015-05-27 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual contra el factor de crecimiento endotelial vascular (vegf) y el ligando involucrado en la señalizacion celula a celula a traves del receptor notch (dll4)
|
JP2015537212A
(ja)
|
2012-11-15 |
2015-12-24 |
ジェネンテック, インコーポレイテッド |
イオン強度媒介のph勾配イオン交換クロマトグラフィー
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
AP2015008365A0
(en)
|
2012-12-05 |
2015-04-30 |
Novartis Ag |
Compositions and methods for antibodies targeting epo
|
AU2013362909A1
(en)
|
2012-12-18 |
2015-05-21 |
Novartis Ag |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
US9458244B2
(en)
|
2012-12-28 |
2016-10-04 |
Abbvie Inc. |
Single chain multivalent binding protein compositions and methods
|
JP2016510319A
(ja)
|
2012-12-28 |
2016-04-07 |
アッヴィ・インコーポレイテッド |
多価結合タンパク質組成物
|
DK2941302T3
(en)
|
2013-01-02 |
2018-10-08 |
Glenmark Pharmaceuticals Sa |
ANTIBODIES BINDING TO TL1A AND THEIR USES
|
WO2014116596A1
(en)
|
2013-01-22 |
2014-07-31 |
Abbvie, Inc. |
Methods for optimizing domain stability of binding proteins
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
WO2014118705A1
(en)
|
2013-01-31 |
2014-08-07 |
Novartis Ag |
Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
|
WO2014120975A1
(en)
|
2013-02-01 |
2014-08-07 |
California Institute Of Technology |
Antibody-mediated immunocontraception
|
KR20150115000A
(ko)
|
2013-02-08 |
2015-10-13 |
아이알엠 엘엘씨 |
면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
CN105247072B
(zh)
|
2013-02-25 |
2019-10-15 |
基因泰克公司 |
检测和治疗抗药性akt突变体的方法和组合物
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
JP6371758B2
(ja)
|
2013-03-12 |
2018-08-08 |
全薬工業株式会社 |
抗ブドウ球菌抗体、その製造方法並びにその使用
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
US9944700B2
(en)
|
2013-03-13 |
2018-04-17 |
Novartis Ag |
Notch2 binding molecules for treating respiratory diseases
|
CN110075293A
(zh)
|
2013-03-13 |
2019-08-02 |
霍夫曼-拉罗奇有限公司 |
氧化降低的配制剂
|
PT2968467T
(pt)
|
2013-03-13 |
2020-07-28 |
Hoffmann La Roche |
Formulações de oxidação reduzida
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
SG10201913932VA
(en)
|
2013-03-13 |
2020-03-30 |
Genentech Inc |
Antibody formulations
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
US9194873B2
(en)
|
2013-03-14 |
2015-11-24 |
Abbott Laboratories |
HCV antigen-antibody combination assay and methods and compositions for use therein
|
JP2016514130A
(ja)
|
2013-03-14 |
2016-05-19 |
ノバルティス アーゲー |
Notch3に対する抗体
|
JP2016512241A
(ja)
|
2013-03-14 |
2016-04-25 |
アボット・ラボラトリーズAbbott Laboratories |
改良された抗体検出のためのhcvns3組換え抗原およびこの突然変異体
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
CN105378099B
(zh)
|
2013-03-14 |
2021-05-11 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
|
DK2970378T3
(da)
|
2013-03-15 |
2021-08-23 |
Biogen Ma Inc |
Hydrofob interaktionsproteinkromatografi under saltfrie betingelser
|
BR112015022529A2
(pt)
|
2013-03-15 |
2017-07-18 |
Genentech Inc |
meios de cultura de células e processos de produção de anticorpo
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
NZ710929A
(en)
|
2013-03-15 |
2018-02-23 |
Novartis Ag |
Antibody drug conjugates
|
CN110951670A
(zh)
|
2013-03-15 |
2020-04-03 |
豪夫迈·罗氏有限公司 |
具有抗氧化剂的细胞培养组合物和多肽生产方法
|
KR102175688B1
(ko)
|
2013-03-27 |
2020-11-06 |
제넨테크, 인크. |
베타7 인테그린 길항제를 사용하는 위장 염증성 장애의 치료를 평가하기 위한 바이오마커의 사용
|
US20160053023A1
(en)
|
2013-04-09 |
2016-02-25 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
WO2014178078A2
(en)
|
2013-04-30 |
2014-11-06 |
Intas Boipharmaceuticals Limited |
Novel cloning, expression & purification method for the preparation of ranibizumab
|
EP3004892B1
(en)
|
2013-05-24 |
2018-10-10 |
Nestec S.A. |
Method for diagnosing irritable bowel syndrome
|
ES2754177T3
(es)
|
2013-06-12 |
2020-04-16 |
Massachusetts Gen Hospital |
Métodos para la detección multiplexada de moléculas diana y sus usos
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
AR096713A1
(es)
*
|
2013-06-25 |
2016-01-27 |
Cadila Healthcare Ltd |
Proceso de purificación para anticuerpos monoclonales
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
CA2916521C
(en)
|
2013-07-09 |
2023-03-07 |
Annexon, Inc. |
Anti-complement factor c1q antibodies and uses thereof
|
SG11201600221YA
(en)
|
2013-07-12 |
2016-02-26 |
Genentech Inc |
Elucidation of ion exchange chromatography input optimization
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
RS60826B1
(sr)
|
2013-07-16 |
2020-10-30 |
Hoffmann La Roche |
Postupci lečenja kancera upotrebom antagonista vezivanja pd-1 ose i tigit inhibitora
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
KR20180021234A
(ko)
|
2013-08-12 |
2018-02-28 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
RU2725825C2
(ru)
|
2013-08-30 |
2020-07-06 |
Иммьюноджен Инк. |
Антитела и методы анализа для обнаружения рецептора фолиевой кислоты 1
|
CA2922832A1
(en)
|
2013-09-05 |
2015-03-12 |
Genentech, Inc. |
Method for chromatography reuse
|
EP3041484B1
(en)
|
2013-09-06 |
2021-03-03 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
WO2015038811A2
(en)
|
2013-09-11 |
2015-03-19 |
Arsia Therapeutics, Inc. |
Liquid protein formulations containing ionic liquids
|
KR20160055253A
(ko)
|
2013-09-12 |
2016-05-17 |
할로자임, 아이엔씨 |
변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
|
EP4331605A3
(en)
|
2013-09-13 |
2024-05-22 |
F. Hoffmann-La Roche AG |
Methods and compositions comprising purified recombinant polypeptides
|
CN105722992B
(zh)
|
2013-09-13 |
2021-04-20 |
豪夫迈·罗氏有限公司 |
用于检测和定量细胞系和重组多肽产物中的宿主细胞蛋白的组合物和方法
|
MY175472A
(en)
|
2013-09-27 |
2020-06-29 |
Genentech Inc |
Anti-pdl1 antibody formulations
|
US9243294B2
(en)
|
2013-09-30 |
2016-01-26 |
Hadasit Medical Research Services And Development Ltd. |
Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
CN105848722B
(zh)
|
2013-10-02 |
2021-09-03 |
免疫医疗有限责任公司 |
中和抗甲型流感抗体及其用途
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
CA2930218C
(en)
|
2013-11-25 |
2020-11-17 |
Ccam Biotherapeutics Ltd. |
Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
|
ES2909014T3
(es)
|
2013-11-26 |
2022-05-04 |
Brigham & Womens Hospital Inc |
Composiciones y métodos para modular una respuesta inmunitaria
|
KR102311761B1
(ko)
|
2013-12-09 |
2021-10-13 |
알라코스 인크. |
항-Siglec-8 항체 및 그의 사용 방법
|
EP3080611B1
(en)
|
2013-12-13 |
2018-11-14 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
MX2016007865A
(es)
|
2013-12-17 |
2017-01-11 |
Novartis Ag |
Peptidos citotoxicos y conjugados de los mismos.
|
JP2017501167A
(ja)
|
2013-12-17 |
2017-01-12 |
ジェネンテック, インコーポレイテッド |
Ox40結合アゴニスト及びpd−1軸結合アンタゴニストを含む併用療法
|
BR112016013896A2
(pt)
|
2013-12-17 |
2017-10-10 |
Genentech Inc |
métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2
|
CN105849124B
(zh)
|
2013-12-20 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
双重特异性抗体
|
WO2015103026A2
(en)
|
2014-01-03 |
2015-07-09 |
The Regents Of The University Of Michigan |
Treatment of neurological disorders
|
EP2891657A1
(en)
|
2014-01-07 |
2015-07-08 |
Centre National de la Recherche Scientifique (CNRS) |
Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10023892B2
(en)
|
2014-05-27 |
2018-07-17 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
KR20160104727A
(ko)
|
2014-01-16 |
2016-09-05 |
아카데미아 시니카 |
암의 치료 및 검출을 위한 조성물 및 방법
|
EP2896400A1
(en)
|
2014-01-17 |
2015-07-22 |
Université Catholique De Louvain |
Method for increasing the bioavailability of inhaled compounds
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
ES2694857T3
(es)
|
2014-02-04 |
2018-12-27 |
Genentech, Inc. |
Smoothened mutante y métodos de uso de la misma
|
EP3102701A1
(en)
|
2014-02-07 |
2016-12-14 |
Novartis AG |
Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
|
AU2015219008B2
(en)
|
2014-02-19 |
2020-10-01 |
University Of Tennessee Research Foundation |
Antibody for skewing sex ratio and methods of use thereof
|
WO2015131155A1
(en)
|
2014-02-28 |
2015-09-03 |
Allakos Inc. |
Methods and compositions for treating siglec-8 associated diseases
|
SG11201606850QA
(en)
|
2014-03-12 |
2016-09-29 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
SI3116999T1
(sl)
|
2014-03-14 |
2021-12-31 |
F. Hoffmann - La Roche Ag |
Postopki in sestavki za izločanje heterolognih polipeptidov
|
EP3119913B1
(en)
|
2014-03-21 |
2021-01-06 |
The Brigham and Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
JP6562942B2
(ja)
|
2014-03-27 |
2019-08-28 |
アカデミア シニカAcademia Sinica |
反応性標識化合物およびその使用
|
KR20220065091A
(ko)
|
2014-03-27 |
2022-05-19 |
제넨테크, 인크. |
염증성 장 질환의 진단 및 치료 방법
|
WO2015145449A2
(en)
|
2014-03-27 |
2015-10-01 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
EP3128997B1
(en)
|
2014-04-08 |
2020-08-05 |
Boston Pharmaceuticals Inc. |
Binding molecules specific for il-21 and uses thereof
|
KR20160143808A
(ko)
|
2014-04-11 |
2016-12-14 |
메디뮨 엘엘씨 |
이중특이적 her2 항체
|
US20170045528A1
(en)
|
2014-04-25 |
2017-02-16 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating subjects with immune-mediated diseases
|
AU2015249946A1
(en)
|
2014-04-25 |
2016-11-17 |
The Brigham And Women's Hospital Inc. |
Methods to manipulate alpha-fetoprotein (AFP)
|
MD20160130A2
(ro)
|
2014-04-27 |
2017-04-30 |
Ccam Biotherapeutics Ltd. |
Anticorpi umanizaţi contra CEACAM1
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
WO2015171822A1
(en)
|
2014-05-06 |
2015-11-12 |
Genentech, Inc. |
Production of heteromultimeric proteins using mammalian cells
|
KR102246800B1
(ko)
|
2014-05-13 |
2021-04-30 |
바이오아트라, 인코퍼레이티드 |
조건부 활성 생체 단백질
|
KR20170003720A
(ko)
|
2014-05-27 |
2017-01-09 |
아카데미아 시니카 |
항-cd20 글리코항체 및 이의 용도
|
KR102512592B1
(ko)
|
2014-05-27 |
2023-03-21 |
아카데미아 시니카 |
항-her2 글리코항체 및 이의 용도
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
US11332523B2
(en)
|
2014-05-28 |
2022-05-17 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
EP3613433B1
(en)
|
2014-05-30 |
2022-01-05 |
Shanghai Henlius Biotech, Inc. |
Anti-epidermal growth factor receptor (egfr) antibodies
|
WO2015191760A2
(en)
|
2014-06-10 |
2015-12-17 |
Abbvie, Inc. |
Compositions and methods for treating rheumatoid arthritis
|
AU2015273098B2
(en)
|
2014-06-13 |
2018-05-10 |
Novartis Ag |
Auristatin derivatives and conjugates thereof
|
EP2957571B1
(en)
|
2014-06-17 |
2018-08-15 |
Centre National De La Recherche Scientifique (Cnrs) |
Monoclonal anti-pvhl antibodies and uses thereof
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
WO2016004055A1
(en)
|
2014-07-03 |
2016-01-07 |
Yale University |
Dickkopf2 (Dkk2) Inhibition Suppresses Tumor Formation
|
AR101210A1
(es)
|
2014-07-15 |
2016-11-30 |
Genentech Inc |
Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
|
CN107257691B
(zh)
|
2014-07-16 |
2021-09-21 |
达娜-法勃肿瘤研究所公司 |
低级别浆液性卵巢癌中的her3抑制
|
JP6956630B2
(ja)
|
2014-07-24 |
2021-11-02 |
ジェネンテック, インコーポレイテッド |
薬剤の少なくとも1つのトリスルフィド結合を含むタンパク質中のチオール部分へのコンジュゲーション方法
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
US9988443B2
(en)
|
2014-08-07 |
2018-06-05 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
WO2016020880A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
CN107106679B
(zh)
|
2014-08-08 |
2022-07-26 |
艾利妥 |
抗trem2抗体及其使用方法
|
EP3180360A1
(en)
|
2014-08-12 |
2017-06-21 |
Novartis AG |
Anti-cdh6 antibody drug conjugates
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
PL3186281T3
(pl)
|
2014-08-28 |
2019-10-31 |
Halozyme Inc |
Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
|
DK3186284T3
(da)
|
2014-08-28 |
2022-05-09 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
CN106795548A
(zh)
|
2014-09-03 |
2017-05-31 |
生物蛋白有限公司 |
在相同的真核细胞产生宿主中发现和产生条件活性生物蛋白
|
US9879042B2
(en)
|
2014-09-08 |
2018-01-30 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
WO2016038550A1
(en)
|
2014-09-11 |
2016-03-17 |
Novartis Ag |
Inhibition of prmt5 to treat mtap-deficiency-related diseases
|
BR112017004393A2
(pt)
|
2014-09-15 |
2018-02-27 |
Genentech Inc |
formulações de anticorpo
|
WO2016044697A1
(en)
|
2014-09-19 |
2016-03-24 |
The Johns Hopkins University |
Biomarkers of cognitive dysfunction
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
|
JP6716577B2
(ja)
|
2014-10-01 |
2020-07-01 |
イーグル・バイオロジクス・インコーポレイテッドEagle Biologics, Inc. |
粘度低下物質を含有する、多糖および核酸の調合薬
|
JP6625627B2
(ja)
|
2014-10-14 |
2019-12-25 |
ハロザイム インコーポレイテッド |
アデノシンデアミナーゼ−2(ada2)、その変異体の組成物およびそれを使用する方法
|
AU2015338974B2
(en)
|
2014-10-31 |
2021-08-26 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
JP6951246B2
(ja)
|
2014-11-05 |
2021-10-20 |
アネクソン,インコーポレーテッド |
ヒト化抗補体因子C1q抗体及びその使用
|
JP6770966B2
(ja)
|
2014-11-05 |
2020-10-21 |
ジェネンテック, インコーポレイテッド |
細菌における2鎖タンパク質の生成方法
|
US10112994B2
(en)
|
2014-11-05 |
2018-10-30 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
EP3215519A1
(en)
|
2014-11-06 |
2017-09-13 |
Novartis AG |
Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
|
SG11201703376QA
(en)
|
2014-11-06 |
2017-05-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
MX2017006094A
(es)
|
2014-11-10 |
2017-07-19 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos.
|
SG11201703332SA
(en)
|
2014-11-10 |
2017-05-30 |
Medimmune Ltd |
Binding molecules specific for cd73 and uses thereof
|
JP2018500882A
(ja)
|
2014-11-10 |
2018-01-18 |
ジェネンテック, インコーポレイテッド |
腎症の動物モデルおよびそれを治療するための薬剤
|
WO2016075176A1
(en)
|
2014-11-11 |
2016-05-19 |
Medimmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
|
US9526768B2
(en)
|
2014-11-13 |
2016-12-27 |
Jennifer Mai |
Compositions for the treatment of cancer
|
US20160166685A1
(en)
|
2014-11-17 |
2016-06-16 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
CN107257805A
(zh)
|
2014-11-19 |
2017-10-17 |
雀巢产品技术援助有限公司 |
抗血清素、色氨酸和犬尿氨酸代谢产物的抗体及其用途
|
EP3221445B1
(en)
|
2014-11-20 |
2021-07-14 |
The Regents of The University of California |
Compositions and methods related to hematologic recovery
|
EP3227446A1
(en)
|
2014-12-01 |
2017-10-11 |
Novartis AG |
Compositions and methods for diagnosis and treatment of prostate cancer
|
WO2016087514A1
(en)
|
2014-12-02 |
2016-06-09 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
EP3029032A1
(en)
|
2014-12-05 |
2016-06-08 |
Centre National de la Recherche Scientifique (CNRS) |
Bifunctional do2pa derivatives, chelates with metallic cations and use thereof
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
JP6827928B2
(ja)
|
2014-12-19 |
2021-02-10 |
ユニヴェルシテ・ドゥ・ナント |
抗il−34抗体
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
IL286835B2
(en)
|
2014-12-22 |
2024-03-01 |
Systimmune Inc |
Bispecific tetravalent antibodies and methods for their preparation and use
|
WO2016115345A1
(en)
|
2015-01-14 |
2016-07-21 |
The Brigham And Women's Hospital, |
Treatment of cancer with anti-lap monoclonal antibodies
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
KR102630294B1
(ko)
|
2015-01-24 |
2024-01-26 |
아카데미아 시니카 |
암 마커 및 이를 사용하는 방법
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
JP2018506275A
(ja)
|
2015-01-28 |
2018-03-08 |
ジェネンテック, インコーポレイテッド |
多発性硬化症の遺伝子発現マーカー及び治療
|
CN107614521B
(zh)
|
2015-01-30 |
2022-02-08 |
台湾地区“中央研究院” |
增进抗体功效的通用糖型组合物及方法
|
MA41451A
(fr)
|
2015-02-04 |
2017-12-12 |
Univ Washington |
Constructions anti-tau
|
WO2016126972A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN107847584B
(zh)
|
2015-02-09 |
2022-01-25 |
纪念斯隆凯特琳癌症中心 |
具有人a33抗原和dota金属复合物亲和力的多特异性抗体及其用途
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
TWI691512B
(zh)
*
|
2015-02-20 |
2020-04-21 |
日商橘生藥品工業股份有限公司 |
Fc融合高親和性IgE受體α鏈
|
CA2976593A1
(en)
|
2015-02-23 |
2016-09-01 |
Seagull Therapeutics Sas |
Non-natural semaphorins 3 and their medical use
|
WO2016138207A1
(en)
|
2015-02-26 |
2016-09-01 |
Genentech, Inc. |
Integrin beta7 antagonists and methods of treating crohn's disease
|
SG11201706918YA
(en)
|
2015-02-26 |
2017-09-28 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
EP3636749B1
(en)
|
2015-03-06 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Ultrapurified dsbc and methods of making and using the same
|
WO2016157195A1
(en)
|
2015-04-01 |
2016-10-06 |
Hadasit Medical Research Services And Development Ltd. |
Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for treatment of liver disorders
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
CA2982115A1
(en)
|
2015-04-06 |
2016-10-13 |
President And Fellows Of Harvard College |
Compositions and methods for non-myeloablative conditioning
|
CA2981851A1
(en)
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof
|
KR20180002653A
(ko)
|
2015-04-07 |
2018-01-08 |
제넨테크, 인크. |
효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
|
EP3281010B1
(en)
|
2015-04-10 |
2020-12-30 |
The Regents of The University of California |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
AU2016252773B2
(en)
|
2015-04-24 |
2022-06-02 |
Genentech, Inc. |
Multispecific antigen-binding proteins
|
EP3913052A1
(en)
|
2015-04-24 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Methods of identifying bacteria comprising binding polypeptides
|
CN107592812A
(zh)
|
2015-05-11 |
2018-01-16 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
US10881733B2
(en)
|
2015-05-22 |
2021-01-05 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
MX2017015011A
(es)
|
2015-05-28 |
2018-03-23 |
Genentech Inc |
Ensayo a base de celulas para detectar homodimeros anti-cd3.
|
PL3303619T3
(pl)
|
2015-05-29 |
2020-10-05 |
F. Hoffmann-La Roche Ag |
Metylacja promotora PD-L1 w chorobach nowotworowych
|
EP3302552A1
(en)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
WO2016193945A2
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
MX2017015690A
(es)
|
2015-06-05 |
2018-07-06 |
Novartis Ag |
Anticuerpos dirigidos a la proteina morfogenetica osea 9 (bmp9) y metodos a partir de estos.
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
WO2016201388A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
JP6876629B2
(ja)
|
2015-06-16 |
2021-05-26 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Pd−l1アンタゴニスト併用療法
|
EP3310385A4
(en)
|
2015-06-17 |
2018-12-19 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
US10077313B2
(en)
|
2015-06-29 |
2018-09-18 |
Immunogen, Inc. |
Anti-CD123 antibodies and conjugates and derivatives thereof
|
AU2016285596A1
(en)
|
2015-06-29 |
2018-01-18 |
Genentech, Inc. |
Type II anti-CD20 antibody for use in organ transplantation
|
WO2017023866A1
(en)
|
2015-07-31 |
2017-02-09 |
Boston Biomedical, Inc. |
Method of targeting stat3 and other non-druggable proteins
|
KR20180035852A
(ko)
|
2015-08-03 |
2018-04-06 |
노파르티스 아게 |
Fgf21-연관 장애를 치료하는 방법
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
JP2018525999A
(ja)
|
2015-08-28 |
2018-09-13 |
アレクトル エルエルシー |
抗Siglec−7抗体及びその使用方法
|
EP3344658B1
(en)
|
2015-09-02 |
2022-05-11 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
|
EP3344806A4
(en)
|
2015-09-04 |
2019-03-20 |
OBI Pharma, Inc. |
GLYCAN NETWORKS AND METHODS OF USE
|
US10000561B2
(en)
|
2015-09-09 |
2018-06-19 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
|
BR112018003326A2
(pt)
|
2015-09-09 |
2018-09-18 |
Novartis Ag |
anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
|
US10894988B2
(en)
|
2015-09-11 |
2021-01-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
CN109071644B
(zh)
|
2015-09-23 |
2023-09-19 |
昂考梅德药品有限公司 |
治疗癌症的方法和组合物
|
US11142565B2
(en)
|
2015-09-24 |
2021-10-12 |
Abvitro Llc |
Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
|
WO2017053748A2
(en)
|
2015-09-25 |
2017-03-30 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
US10954300B2
(en)
|
2015-09-28 |
2021-03-23 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
CA3000386A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
US20190330335A1
(en)
|
2015-10-06 |
2019-10-31 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
JP2018529747A
(ja)
|
2015-10-06 |
2018-10-11 |
ジェネンテック, インコーポレイテッド |
多発性硬化症を治療するための方法
|
EP3362093A4
(en)
|
2015-10-13 |
2019-05-08 |
Technion Research & Development Foundation Limited |
MONOCLONAL ANTIBODIES NEUTRALIZING HEPARANASE
|
WO2017070594A1
(en)
|
2015-10-21 |
2017-04-27 |
William John Hall |
Bed bugs detection device
|
EP3365367B1
(en)
|
2015-10-21 |
2023-06-07 |
Redcoat Solutions, Inc. |
Anti-bed bug monoclonal antibodies and methods of making and uses thereof
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
RU2018119317A
(ru)
|
2015-10-28 |
2019-12-04 |
Йейл Юниверсити |
Гуманизированное антитело к dkk2 и его применение
|
CN116003596A
(zh)
|
2015-10-29 |
2023-04-25 |
艾利妥 |
抗siglec-9抗体及其使用方法
|
JP6898925B2
(ja)
|
2015-11-10 |
2021-07-07 |
メディミューン,エルエルシー |
Asct2特異的結合分子及びその使用
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
WO2017089593A1
(en)
|
2015-11-26 |
2017-06-01 |
Universite Paris Descartes |
Inhibitors for treating or preventing a pulmonary arterial hypertension in systemic sclerosis patients and method for diagnosing said disease
|
KR102165120B1
(ko)
|
2015-12-15 |
2020-10-13 |
길리애드 사이언시즈, 인코포레이티드 |
인간 면역결핍 바이러스 중화 항체
|
EP3390455A1
(en)
|
2015-12-17 |
2018-10-24 |
Janssen Pharmaceutica NV |
Antibodies to quetiapine and use thereof
|
AU2016372069A1
(en)
|
2015-12-17 |
2018-06-07 |
Saladax Biomedical Inc. |
Antibodies to risperidone and use thereof
|
WO2017103895A1
(en)
|
2015-12-18 |
2017-06-22 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
EP3395835B1
(en)
|
2015-12-25 |
2021-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
CN108368166B
(zh)
|
2015-12-28 |
2023-03-28 |
中外制药株式会社 |
提高含fc区多肽纯化效率的方法
|
EP3397243A1
(en)
|
2015-12-30 |
2018-11-07 |
H. Hoffnabb-La Roche Ag |
Use of tryptophan derivatives for protein formulations
|
BR112018010945A2
(pt)
|
2015-12-30 |
2018-12-04 |
Genentech Inc |
formulações com degradação de polissorbato reduzida
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
AU2017208133B2
(en)
|
2016-01-11 |
2023-12-21 |
Universitat Zurich |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
MA55746A
(fr)
|
2016-01-21 |
2022-03-02 |
Novartis Ag |
Molécules multispécifiques ciblant cll-1
|
CN109073635A
(zh)
|
2016-01-25 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于测定t细胞依赖性双特异性抗体的方法
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
TW201734041A
(zh)
|
2016-02-19 |
2017-10-01 |
莫菲西斯公司 |
抗il-17c抗體
|
US11066456B2
(en)
|
2016-02-25 |
2021-07-20 |
Washington University |
Compositions comprising TREM2 and methods of use thereof
|
MX2018010445A
(es)
|
2016-03-01 |
2019-10-17 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticuerpos especificos del receptor de poliovirus humano (rvp).
|
US10655125B2
(en)
|
2016-03-04 |
2020-05-19 |
Mor0059Us.Np |
Polypeptide library
|
US11472877B2
(en)
|
2016-03-04 |
2022-10-18 |
Alector Llc |
Anti-TREM1 antibodies and methods of use thereof
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
EP3426693A4
(en)
|
2016-03-08 |
2019-11-13 |
Academia Sinica |
PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
|
CN109153713B
(zh)
|
2016-03-10 |
2022-12-27 |
艾科赛扬制药股份有限公司 |
活化素2型受体结合蛋白及其用途
|
TW202248213A
(zh)
|
2016-03-15 |
2022-12-16 |
日商中外製藥股份有限公司 |
使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
CA3018124A1
(en)
|
2016-03-23 |
2017-09-28 |
Prothix Bv |
Monoclonal antibodies against the active site of factor xi and uses thereof
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
JP7208010B2
(ja)
|
2016-03-29 |
2023-01-18 |
ユニバーシティ オブ サザン カリフォルニア |
癌を標的とするキメラ抗原受容体
|
KR20180121786A
(ko)
|
2016-03-29 |
2018-11-08 |
오비아이 파머 인코퍼레이티드 |
항체, 제약 조성물 및 방법
|
CA3018253A1
(en)
|
2016-03-31 |
2017-10-05 |
University Of Southern California |
A highly sensitive and specific luciferase based reporter assay for antigen detection
|
EP3445395A4
(en)
|
2016-04-22 |
2019-12-25 |
OBI Pharma, Inc. |
ANTI-CANCER IMMUNOTHERAPY BY IMMUNO-ACTIVATION OR IMMUNOMODULATION THROUGH GLOBO SERIES ANTIGENS
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
JP7138567B2
(ja)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
成長分化因子15に対する抗体およびそれらの使用
|
EP3452492A1
(en)
|
2016-05-05 |
2019-03-13 |
Novartis AG |
Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
|
IL262404B2
(en)
|
2016-05-13 |
2024-04-01 |
Bioatla Llc |
Antibodies, Antibody Fragments and Their Immunomodules Against ROR2 and Their Uses
|
JP7359547B2
(ja)
|
2016-05-17 |
2023-10-11 |
ジェネンテック, インコーポレイテッド |
免疫療法における診断及び使用のための間質遺伝子シグネチャー
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
RU2018145184A
(ru)
|
2016-05-26 |
2020-06-26 |
Мерк Патент Гмбх |
Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования
|
CA3025377A1
(en)
|
2016-06-02 |
2017-12-07 |
Abbvie Inc. |
Glucocorticoid receptor agonist and immunoconjugates thereof
|
WO2017207694A1
(en)
|
2016-06-02 |
2017-12-07 |
Kohlmann Angelica |
Antibodies that bind to human anti-müllerian hormone (amh) and their uses
|
CN110381988A
(zh)
|
2016-06-15 |
2019-10-25 |
诺华股份有限公司 |
使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
|
MX2018015173A
(es)
|
2016-06-17 |
2019-07-04 |
Genentech Inc |
Purificacion de anticuerpos multiespecificos.
|
LT3263715T
(lt)
|
2016-06-28 |
2020-06-25 |
Hifibio |
Pavienių ląstelių transkriptomo analizės būdas
|
EP3263706A1
(en)
|
2016-06-28 |
2018-01-03 |
Centre National De La Recherche Scientifique (Cnrs) |
Agents targeting snat7 for treating cellular metabolism reprogramming-associated diseases
|
WO2018011691A1
(en)
|
2016-07-12 |
2018-01-18 |
Nestec S.A. |
Competitive immunoassay methods
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
BR112019001656A2
(pt)
|
2016-07-27 |
2019-05-28 |
Obi Pharma Inc |
composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo
|
EP3491022A1
(en)
|
2016-07-29 |
2019-06-05 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Antibodies targeting tumor associated macrophages and uses thereof
|
EP3491026A4
(en)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
WO2018026969A2
(en)
|
2016-08-03 |
2018-02-08 |
Achaogen, Inc. |
Plazomicin antibodies and methods of use
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
CN109562153A
(zh)
|
2016-08-07 |
2019-04-02 |
诺华股份有限公司 |
mRNA介导的免疫方法
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
EP3497440A1
(en)
|
2016-08-15 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
|
CA3031742A1
(en)
|
2016-08-16 |
2018-02-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for quantitating individual antibodies from a mixture
|
TWI764917B
(zh)
|
2016-08-22 |
2022-05-21 |
醣基生醫股份有限公司 |
抗體、結合片段及使用方法
|
US11066477B2
(en)
|
2016-08-31 |
2021-07-20 |
Oncotherapy Science, Inc. |
Monoclonal antibody against MELK and utilization thereof
|
WO2018045210A1
(en)
|
2016-09-02 |
2018-03-08 |
Therapeutics Lp 180 |
Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
|
WO2018045213A1
(en)
|
2016-09-02 |
2018-03-08 |
180 Therapeutics Lp |
Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
|
CN109661241A
(zh)
|
2016-09-06 |
2019-04-19 |
中外制药株式会社 |
使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
|
EP3510046A4
(en)
|
2016-09-07 |
2020-05-06 |
The Regents of the University of California |
ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
KR102391338B1
(ko)
|
2016-09-16 |
2022-04-26 |
상하이 헨리우스 바이오테크, 인크. |
항-pd-1 항체
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
TWI762516B
(zh)
|
2016-10-06 |
2022-05-01 |
日商腫瘤療法 科學股份有限公司 |
針對fzd10之單株抗體及其用途
|
EP3522923A1
(en)
|
2016-10-06 |
2019-08-14 |
Pfizer Inc |
Dosing regimen of avelumab for the treatment of cancer
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
DK3532838T3
(da)
|
2016-10-25 |
2022-07-04 |
Regeneron Pharma |
Fremgangsmåder og systemer til kromatografidataanalyse
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
WO2018081649A1
(en)
|
2016-10-28 |
2018-05-03 |
Banyan Biomarkers, Inc. |
Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
US11339209B2
(en)
|
2016-11-14 |
2022-05-24 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
CA3044274A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
EP3541358A1
(en)
|
2016-11-21 |
2019-09-25 |
Eirion Therapeutics, Inc. |
Transdermal delivery of large agents
|
US20230192896A1
(en)
|
2016-11-23 |
2023-06-22 |
Bioverativ Therapeutics Inc. |
Bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
IL300095A
(en)
|
2016-11-23 |
2023-03-01 |
Translational Drug Dev Llc |
Compositions of benzamide and an agonist for the cancer necrosis factor receptor superfamily and uses thereof
|
US10852271B2
(en)
|
2016-12-14 |
2020-12-01 |
Taiwan Semiconductor Manufacturing Co., Ltd. |
On-chip heater
|
CN110300761B
(zh)
|
2016-12-15 |
2023-05-09 |
国家生物技术研究所公司 |
抗pcna单克隆抗体及其用途
|
WO2018118780A1
(en)
*
|
2016-12-19 |
2018-06-28 |
Calico Biolabs, Inc. |
Monovalent and divalent binding proteins
|
JOP20190155A1
(ar)
|
2016-12-21 |
2019-06-23 |
Novartis Ag |
مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
|
US11168147B2
(en)
|
2016-12-23 |
2021-11-09 |
Novartis Ag |
Factor XI antibodies and methods of use
|
JP7110199B2
(ja)
|
2016-12-23 |
2022-08-01 |
ノバルティス アーゲー |
抗第XI/XIa因子抗体による処置法
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
AU2018218557B9
(en)
|
2017-02-08 |
2021-06-24 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
EP3580341A4
(en)
|
2017-02-09 |
2020-11-04 |
Indapta Therapeutics, Inc. |
MANIPULATED NATURAL KILLER (NK) CELLS AND COMPOSITIONS AND METHOD FOR THEREFORE
|
UA126574C2
(uk)
|
2017-02-10 |
2022-11-02 |
Дженентек, Інк. |
Антитіло проти триптази, його композиція та застосування
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
CN108456251A
(zh)
|
2017-02-21 |
2018-08-28 |
上海君实生物医药科技股份有限公司 |
抗pd-l1抗体及其应用
|
CN110392697A
(zh)
|
2017-03-02 |
2019-10-29 |
国家医疗保健研究所 |
对nectin-4具有特异性的抗体及其用途
|
LT3375889T
(lt)
|
2017-03-17 |
2020-06-25 |
Hifibio Sas |
Vienos ląstelės analizė
|
BR112019019939A2
(pt)
|
2017-03-30 |
2020-04-28 |
Merck Patent Gmbh |
combinação de anticorpo anti-pd-l1 e um inibidor de dna-pk para tratamento de câncer
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
TW201836636A
(zh)
|
2017-03-31 |
2018-10-16 |
公立大學法人奈良縣立醫科大學 |
含有替代凝血因子viii功能之多特異性抗原結合分子之用於預防和/或治療凝血因子ix異常症的醫藥組合物
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
CN110352201A
(zh)
|
2017-04-03 |
2019-10-18 |
免疫医疗公司 |
用于癌症疗法的抗体药物缀合物的皮下施用
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
EP4230649A3
(en)
|
2017-04-25 |
2023-10-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
MX2019012793A
(es)
|
2017-04-27 |
2020-02-13 |
Tesaro Inc |
Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
|
US11203638B2
(en)
|
2017-05-05 |
2021-12-21 |
Allakos Inc. |
Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis
|
EP3652537A4
(en)
|
2017-05-05 |
2021-10-20 |
Memorial Sloan Kettering Cancer Center |
MODULAR SELF-ASSEMBLY / DISASSEMBLY TECHNOLOGIES (SADA)
|
EP3624846A1
(en)
|
2017-05-16 |
2020-03-25 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
US11359014B2
(en)
|
2017-05-16 |
2022-06-14 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
CN117587524A
(zh)
|
2017-06-22 |
2024-02-23 |
莫佛塞斯公司 |
犬抗体文库
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
WO2019005757A1
(en)
|
2017-06-27 |
2019-01-03 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF CTLA4 ANTAGONIST RESISTANCE IN LEUKEMIA
|
CN111094334A
(zh)
|
2017-07-19 |
2020-05-01 |
美国卫生与公众服务部 |
用于诊断和治疗乙肝病毒感染的抗体和方法
|
WO2019018729A1
(en)
|
2017-07-20 |
2019-01-24 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
|
EP3658581A1
(en)
|
2017-07-24 |
2020-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies and peptides to treat hcmv related diseases
|
WO2019020807A1
(en)
|
2017-07-28 |
2019-01-31 |
Gene Signal International Sa |
CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
|
WO2019023525A1
(en)
|
2017-07-28 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS
|
RS64419B1
(sr)
|
2017-08-03 |
2023-09-29 |
Alector Llc |
Anti-trem2 antitela i postupci za njihovu upotrebu
|
CA3057447A1
(en)
|
2017-08-03 |
2019-02-07 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
MX2020000903A
(es)
|
2017-08-11 |
2020-07-22 |
Genentech Inc |
Anticuerpos anti-cd8 y usos de los mismos.
|
EP3668898B1
(en)
|
2017-08-14 |
2023-07-05 |
MorphoSys AG |
Humanized antibodies for cd3
|
JP7382922B2
(ja)
|
2017-09-20 |
2023-11-17 |
中外製薬株式会社 |
Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン
|
CA3076547A1
(en)
|
2017-09-20 |
2019-03-28 |
The University Of British Columbia |
Novel anti-hla-a2 antibodies and uses thereof
|
TW201919698A
(zh)
|
2017-09-25 |
2019-06-01 |
德商莫菲西斯公司 |
異位性皮炎之治療
|
WO2019063958A1
(en)
|
2017-09-27 |
2019-04-04 |
The University Of York |
BIOCONJUGATION OF POLYPEPTIDES
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
KR20200063153A
(ko)
|
2017-10-10 |
2020-06-04 |
누맙 세러퓨틱스 아게 |
Cd137을 표적화하는 항체 및 이의 사용 방법
|
EP3470428A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Innovation AG |
Antibodies targeting cd137 and methods of use thereof
|
CA3077509A1
(en)
|
2017-10-10 |
2019-04-18 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
EP3470429A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Innovation AG |
Antibodies targeting pdl1 and methods of use thereof
|
CA3074802A1
(en)
|
2017-10-10 |
2019-04-18 |
Numab Therapeutics AG |
Antibodies targeting pdl1 and methods of use thereof
|
JP2020536967A
(ja)
|
2017-10-12 |
2020-12-17 |
イミュノウェイク インコーポレイテッド |
Vegfr−抗体軽鎖融合タンパク質
|
WO2019079362A1
(en)
|
2017-10-16 |
2019-04-25 |
Massachusetts Institute Of Technology |
HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
BR112020008393A2
(pt)
*
|
2017-11-01 |
2020-11-03 |
Chugai Seiyaku Kabushiki Kaisha |
variante e isoforma de anticorpos com atividade biológica reduzida
|
EP3713965A1
(en)
|
2017-11-22 |
2020-09-30 |
Novartis AG |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
WO2019102456A1
(en)
|
2017-11-27 |
2019-05-31 |
University Of Rijeka Faculty Of Medicine |
Immunotoxins for treating cancer
|
CA3083363A1
(en)
|
2017-12-01 |
2019-06-06 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
US11332736B2
(en)
|
2017-12-07 |
2022-05-17 |
The Broad Institute, Inc. |
Methods and compositions for multiplexing single cell and single nuclei sequencing
|
AU2018388791A1
(en)
|
2017-12-19 |
2020-07-16 |
The Rockefeller University |
Human IgG Fc domain variants with improved effector function
|
WO2019122054A1
(en)
*
|
2017-12-22 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
JP7383617B2
(ja)
|
2017-12-28 |
2023-11-20 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Pd-l1に対する抗体及びそのバリアント
|
CA3082280A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against tigit
|
EP3732193A1
(en)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
BR112020013236A2
(pt)
|
2018-01-03 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
|
JP7366908B2
(ja)
|
2018-01-15 |
2023-10-23 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Pd-1に対する単一ドメイン抗体及びその変異体
|
WO2019152715A1
(en)
|
2018-01-31 |
2019-08-08 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
CA3226165A1
(en)
|
2018-02-09 |
2019-08-15 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
US11512127B2
(en)
|
2018-02-14 |
2022-11-29 |
Viela Bio, Inc. |
Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
|
KR20200135313A
(ko)
|
2018-02-26 |
2020-12-02 |
제넨테크, 인크. |
항-tigit 및 항-pd-l1 길항제 항체에 의한 치료를 위한 투약
|
CA3093295A1
(en)
|
2018-03-06 |
2019-09-12 |
Imcare Biotech, Llc |
Serine protease inhibitor kazal (spik) compositions and methods
|
GB201803563D0
(en)
|
2018-03-06 |
2018-04-18 |
Galapagos Nv |
Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
|
TW202003562A
(zh)
|
2018-03-14 |
2020-01-16 |
中國大陸商北京軒義醫藥科技有限公司 |
抗密連蛋白18.2(cldn18.2)抗體
|
WO2019175885A1
(en)
|
2018-03-15 |
2019-09-19 |
Biond Biologics Ltd. |
Methods and compositions for decreasing soluble immune receptor cd28
|
MX2020009774A
(es)
|
2018-03-21 |
2020-10-08 |
Alx Oncology Inc |
Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
|
SG11202006674QA
(en)
|
2018-03-30 |
2020-08-28 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies against lag-3 and uses thereof
|
EP3774883A1
(en)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
EP3773721A4
(en)
|
2018-04-13 |
2022-01-26 |
Genentech, Inc. |
STABLE ANTI-CD79B IMMUNOCONJUGATE FORMULATIONS
|
CN111989121A
(zh)
|
2018-04-16 |
2020-11-24 |
默克专利股份有限公司 |
高浓缩蛋白质制剂的粘度降低
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
WO2019213416A1
(en)
|
2018-05-02 |
2019-11-07 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
BR112020022145A2
(pt)
|
2018-05-04 |
2021-01-26 |
Merck Patent Gmbh |
inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
|
US20210386829A1
(en)
|
2018-05-04 |
2021-12-16 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
|
KR20210009308A
(ko)
|
2018-05-09 |
2021-01-26 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
인간 넥틴4에 특이적인 항체
|
KR20210021467A
(ko)
|
2018-05-14 |
2021-02-26 |
웨어울프 세라퓨틱스, 인크. |
활성화가능한 인터루킨-2 폴리펩타이드 및 이의 사용 방법
|
AU2019271147A1
(en)
|
2018-05-14 |
2020-12-17 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
EP3793596A1
(en)
|
2018-05-16 |
2021-03-24 |
MorphoSys AG |
Antibodies targeting glycoprotein vi
|
AU2019274782A1
(en)
|
2018-05-24 |
2020-12-03 |
Ares Trading S.A. |
Method for controlling the afucosylation level of a glycoprotein composition
|
KR20210015872A
(ko)
|
2018-05-25 |
2021-02-10 |
알렉터 엘엘씨 |
항-sirpa 항체 및 그의 사용 방법
|
AU2019278875A1
(en)
|
2018-05-31 |
2020-10-22 |
Glyconex Inc. |
Therapeutic antibodies binding to biantennary Lewis B and Lewis Y antigens
|
US11932681B2
(en)
|
2018-05-31 |
2024-03-19 |
Novartis Ag |
Hepatitis B antibodies
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
CA3100626A1
(en)
|
2018-06-08 |
2019-12-12 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
TW202014209A
(zh)
|
2018-06-20 |
2020-04-16 |
瑞士商諾華公司 |
用於消融造血幹細胞之抗體藥物軛合物
|
CN112585166A
(zh)
|
2018-06-23 |
2021-03-30 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
MA53015A
(fr)
|
2018-06-29 |
2021-05-05 |
Alector Llc |
Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
|
WO2020007822A1
(en)
|
2018-07-02 |
2020-01-09 |
Conservatoire National Des Arts Et Metiers (Cnam) |
Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
|
TW202005694A
(zh)
|
2018-07-02 |
2020-02-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
TW202011995A
(zh)
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
PE20210186A1
(es)
|
2018-07-13 |
2021-02-02 |
Alector Llc |
Anticuerpos anti-sortilina y metodos para su uso
|
US20200171146A1
(en)
|
2018-07-18 |
2020-06-04 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
JP2021531027A
(ja)
|
2018-07-27 |
2021-11-18 |
アレクトル エルエルシー |
抗Siglec−5抗体及びその使用方法
|
SG11202100601TA
(en)
|
2018-08-08 |
2021-02-25 |
Genentech Inc |
Use of tryptophan derivatives and l-methionine for protein formulation
|
WO2020041541A2
(en)
|
2018-08-23 |
2020-02-27 |
Seattle Genetics, Inc. |
Anti-tigit antibodies
|
MX2021002299A
(es)
|
2018-08-31 |
2021-04-28 |
Alector Llc |
Anticuerpos de anti-cd33 y metodos para usarlos.
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
WO2020053122A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
CA3114024A1
(en)
|
2018-09-26 |
2020-04-02 |
Merck Patent Gmbh |
Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
|
EP4321530A3
(en)
|
2018-09-27 |
2024-05-22 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
EP3636320A1
(en)
|
2018-10-09 |
2020-04-15 |
Numab Therapeutics AG |
Antibodies targeting cd137 and methods of use thereof
|
CN112805068A
(zh)
|
2018-10-09 |
2021-05-14 |
努玛治疗有限公司 |
靶向cd137的抗体及其使用方法
|
CN113329769A
(zh)
|
2018-10-11 |
2021-08-31 |
斯克里普斯研究学院 |
具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
|
US20220411783A1
(en)
|
2018-10-12 |
2022-12-29 |
The Broad Institute, Inc. |
Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
|
US20210369705A1
(en)
|
2018-10-15 |
2021-12-02 |
Merck Patent Gmbh |
Combination therapy utilizing dna alkylating agents and atr inhibitors
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
AU2019370485A1
(en)
|
2018-11-02 |
2021-05-13 |
Annexon, Inc. |
Compositions and methods for treating brain injury
|
KR20210090645A
(ko)
|
2018-11-05 |
2021-07-20 |
제넨테크, 인크. |
원핵 숙주 세포에서 2개의 사슬 단백질을 생산하는 방법
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
GB201818618D0
(en)
|
2018-11-15 |
2019-01-02 |
Amlo Biosciences Ltd |
Monoclonal antibodies against ambra-1
|
GB201818622D0
(en)
|
2018-11-15 |
2019-01-02 |
Amlo Biosciences Ltd |
Monoclonal antibodies against loricrin
|
US20220008466A1
(en)
|
2018-11-21 |
2022-01-13 |
Indapta Therapeutics, Inc |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|
BR112021009554A2
(pt)
|
2018-12-03 |
2021-08-17 |
Eirion Therapeutics, Inc. |
aplicação melhorada de agentes grandes
|
CA3121699A1
(en)
|
2018-12-05 |
2020-06-11 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
TWI821474B
(zh)
|
2018-12-07 |
2023-11-11 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Cd3抗體及其藥物用途
|
CA3122902A1
(en)
|
2018-12-14 |
2020-06-18 |
Morphosys Ag |
Antibody formulations
|
JP2022514837A
(ja)
|
2018-12-18 |
2022-02-16 |
ノバルティス アーゲー |
抗第XI/XIa因子抗体に対する反転結合剤及びそれらの使用
|
EP3898688A1
(en)
|
2018-12-18 |
2021-10-27 |
Catapult Therapeutics B.V. |
The use of anti-ccr7 mabs for the prevention or treatment of graft-versus-host disease (gvhd)
|
TW202039554A
(zh)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
抗TNF-α抗體
|
WO2020132231A1
(en)
|
2018-12-21 |
2020-06-25 |
Genentech, Inc. |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
CN115947849A
(zh)
|
2018-12-21 |
2023-04-11 |
江苏恒瑞医药股份有限公司 |
双特异性蛋白
|
WO2020128612A2
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Antibodies to pmel17 and conjugates thereof
|
EP3902823A1
(en)
|
2018-12-24 |
2021-11-03 |
Sanofi |
Multispecific binding proteins with mutant fab domains
|
WO2020139926A2
(en)
|
2018-12-26 |
2020-07-02 |
Akrevia Therapeutics Inc. |
Anti-ctla4 antibodies and methods of use thereof
|
KR20210111792A
(ko)
|
2018-12-28 |
2021-09-13 |
스팍스 테라퓨틱스 인크. |
암 및 다른 질환을 치료하기 위한 클라우딘 18.2에 특이적인 결합 분자, 이의 조성물 및 방법
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
JP2022519341A
(ja)
|
2019-01-13 |
2022-03-23 |
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー. |
ヒトネクチン-2に特異的な抗体
|
TW202043272A
(zh)
|
2019-01-14 |
2020-12-01 |
美商建南德克公司 |
使用pd-1軸結合拮抗劑及rna疫苗治療癌症之方法
|
AU2020215795A1
(en)
|
2019-01-31 |
2021-07-29 |
Numab Therapeutics AG |
Multispecific antibodies having specificity for TNFA and IL-17A, antibodies targeting IL-17A, and methods of use thereof
|
EP3689907A1
(en)
|
2019-01-31 |
2020-08-05 |
Numab Therapeutics AG |
Antibodies targeting il-17a and methods of use thereof
|
MX2021010313A
(es)
|
2019-02-27 |
2021-09-23 |
Genentech Inc |
Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
|
BR112021016984A2
(pt)
|
2019-03-01 |
2021-11-30 |
Allogene Therapeutics Inc |
Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
|
JP2022523543A
(ja)
|
2019-03-06 |
2022-04-25 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
二機能性融合タンパク質及びその医薬的使用
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
US20220169732A1
(en)
|
2019-03-14 |
2022-06-02 |
Biond Biologics Ltd. |
Small shedding blocking agents
|
US20220143148A1
(en)
|
2019-03-14 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
|
US20220135658A1
(en)
|
2019-03-14 |
2022-05-05 |
Morphosys Ag |
Antibodies targeting c5ar
|
US20220144965A1
(en)
|
2019-03-15 |
2022-05-12 |
Morphosys Ag |
Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
|
US20220152148A1
(en)
|
2019-03-18 |
2022-05-19 |
The Broad Institute, Inc. |
Modulation of type 2 immunity by targeting clec-2 signaling
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
US20220185875A1
(en)
|
2019-03-18 |
2022-06-16 |
Jiangsu Hengrui Medicine Co., Ltd. |
Bispecific antibody specifically bound to vegf and ang2
|
WO2020193520A1
(en)
|
2019-03-25 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of taupathy disorders by targeting new tau species
|
SG11202110043TA
(en)
|
2019-04-01 |
2021-10-28 |
Genentech Inc |
Compositions and methods for stabilizing protein-containing formulations
|
EP3956664A1
(en)
|
2019-04-18 |
2022-02-23 |
Genentech, Inc. |
Antibody potency assay
|
WO2020213724A1
(ja)
|
2019-04-19 |
2020-10-22 |
中外製薬株式会社 |
抗体改変部位認識キメラ受容体
|
RU2734432C1
(ru)
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
CA3133821A1
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
GB201906297D0
(en)
|
2019-05-03 |
2019-06-19 |
Amlo Biosciences Ltd |
Biomarkers for disease progression in squamous cell carcinoma
|
MX2021013101A
(es)
|
2019-05-03 |
2022-01-04 |
Morphosys Ag |
Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
|
GB201906302D0
(en)
|
2019-05-03 |
2019-06-19 |
Amlo Biosciences Ltd |
Methods of determining the margin of a tumour
|
SG11202112382WA
(en)
|
2019-05-07 |
2021-12-30 |
Gracell Biotechnologies Shanghai Co Ltd |
Engineered immune cell targeting bcma and use thereof
|
AU2020275877A1
(en)
|
2019-05-14 |
2021-12-23 |
Werewolf Therapeutics, Inc. |
Separation moieties and methods and use thereof
|
CA3139983A1
(en)
|
2019-05-14 |
2020-11-19 |
Eirion Therapeutics, Inc. |
Delaying peak effect and/or extending duration of response
|
WO2020232262A1
(en)
|
2019-05-16 |
2020-11-19 |
Procisedx Inc. |
Assay detection methods for vcam-1 and calprotectin
|
EP3821250B1
(en)
|
2019-05-16 |
2022-05-04 |
ProciseDx Inc. |
An assay method for the detection of vcam-1 and alpha-2-macroglobulin in blood
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
US20220396631A1
(en)
|
2019-05-21 |
2022-12-15 |
Lu HUANG |
Trispecific binding molecules against bcma and uses thereof
|
EP3972998A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
JP2022534227A
(ja)
|
2019-05-23 |
2022-07-28 |
プロサイセデクス インコーポレイティド |
ヒト血清アルブミン、ビタミンd、c反応性タンパク質、及び抗トランスグルタミナーゼ自己抗体の検出のためのアッセイ方法
|
US20220243178A1
(en)
|
2019-05-31 |
2022-08-04 |
The Broad Institute, Inc. |
Methods for treating metabolic disorders by targeting adcy5
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
WO2020247159A1
(en)
|
2019-06-06 |
2020-12-10 |
Procisedx Inc. |
DETECTION OF HEMOGLOBIN A1C (HbA1c) IN BLOOD
|
TW202112817A
(zh)
|
2019-06-11 |
2021-04-01 |
美商阿列克特有限責任公司 |
抗揀選蛋白抗體之使用方法
|
UY38747A
(es)
|
2019-06-12 |
2021-01-29 |
Novartis Ag |
Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
|
CA3144324A1
(en)
|
2019-06-24 |
2020-12-30 |
Novartis Ag |
Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
|
EP3990922A1
(en)
|
2019-06-25 |
2022-05-04 |
ProciseDx Inc. |
Detection of anti-tnf alpha drug biologics and anti-drug antibodies
|
AR119293A1
(es)
|
2019-06-28 |
2021-12-09 |
Genentech Inc |
Composición y métodos para estabilizar formulaciones líquidas de proteínas
|
US20220273810A1
(en)
|
2019-07-08 |
2022-09-01 |
Imcare Biotech, Llc |
Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
|
WO2021005232A1
(en)
|
2019-07-11 |
2021-01-14 |
Umc Utrecht Holding B.V. |
Intranasal administration of neutralising antiviral antibodies
|
JPWO2021010326A1
(xx)
|
2019-07-12 |
2021-01-21 |
|
|
BR112022000876A2
(pt)
|
2019-07-19 |
2022-04-26 |
Oncoresponse Inc |
Anticorpos imunomoduladores e métodos de uso destes
|
WO2021016598A1
(en)
|
2019-07-25 |
2021-01-28 |
Immunowake Inc. |
Methods of measuring cell-mediated killing by effectors
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
JP2022542964A
(ja)
|
2019-07-31 |
2022-10-07 |
アレクトル エルエルシー |
抗ms4a4a抗体、及びその使用方法
|
GB201911210D0
(en)
|
2019-08-06 |
2019-09-18 |
Amlo Biosciences Ltd |
Clinical management of oropharyngeal squamous cell carcinoma
|
JP7284256B2
(ja)
|
2019-08-12 |
2023-05-30 |
ビオンド バイオロジクス リミテッド |
Ilt2に対する抗体およびその使用
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
WO2021046159A1
(en)
|
2019-09-04 |
2021-03-11 |
Genentech, Inc. |
Cd8 binding agents and uses thereof
|
JP2022547168A
(ja)
|
2019-09-09 |
2022-11-10 |
スクライブ・セラピューティクス・インコーポレイテッド |
免疫療法に使用するための組成物および方法
|
CA3150538A1
(en)
|
2019-09-11 |
2021-03-18 |
Xuanyong Lu |
KAZAL INHIBITOR ANTI-SERINE PROTEASE (SPIK) ANTIBODY EPITOPES
|
CA3146616A1
(en)
|
2019-09-12 |
2021-03-18 |
Matthew Dominic CASCINO |
Compositions and methods of treating lupus nephritis
|
WO2021053001A1
(en)
|
2019-09-17 |
2021-03-25 |
Merck Patent Gmbh |
Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
|
TW202126699A
(zh)
|
2019-09-20 |
2021-07-16 |
美商建南德克公司 |
用於抗類胰蛋白酶抗體之投藥
|
AU2020351734A1
(en)
|
2019-09-27 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
WO2021058763A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
GB201914399D0
(en)
|
2019-10-04 |
2019-11-20 |
Univ Newcastle |
Biomarkers for assessing explant organ viability
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
BR112022017162A2
(pt)
|
2019-10-31 |
2022-10-18 |
Morphosys Ag |
Terapia anti-cd19 em combinação com lenalidomida para o tratamento de leucemia ou linfoma
|
AU2020372646A1
(en)
|
2019-10-31 |
2022-05-12 |
Incyte Corporation |
Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells
|
EP4051279A1
(en)
|
2019-11-01 |
2022-09-07 |
Ares Trading S.A. |
COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
|
CA3155219A1
(en)
|
2019-11-05 |
2021-05-14 |
Merck Patent Gmbh |
Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
|
WO2021092196A1
(en)
|
2019-11-05 |
2021-05-14 |
Merck Patent Gmbh |
Anti-tigit antibodies and uses thereof
|
IL292458A
(en)
|
2019-11-06 |
2022-06-01 |
Genentech Inc |
Diagnostic and treatment methods for the treatment of hematological cancer
|
AU2020397888A1
(en)
|
2019-12-05 |
2022-06-09 |
Alector Llc |
Methods of use of anti-TREM2 antibodies
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
US20230020548A1
(en)
|
2019-12-09 |
2023-01-19 |
Novartis Ag |
Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
|
US20230227559A1
(en)
|
2019-12-10 |
2023-07-20 |
Institut Pasteur |
New antibody blocking human fcgriiia and fcgriiib
|
BR112022011337A2
(pt)
|
2019-12-12 |
2022-08-23 |
Alector Llc |
Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo
|
CR20220329A
(es)
|
2019-12-13 |
2022-11-23 |
Alector Llc |
Anticuerpos anti–mertk y metodos de uso de los mismos
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
TW202142230A
(zh)
|
2020-01-27 |
2021-11-16 |
美商建南德克公司 |
用於以抗tigit拮抗體抗體治療癌症之方法
|
WO2021151974A1
(en)
|
2020-01-28 |
2021-08-05 |
Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis |
Interfering with mrna splicing to enhance response to checkpoint immunotherapies.
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|
AU2021212197A1
(en)
|
2020-01-31 |
2022-08-04 |
BioNTech SE |
Methods of inducing neoepitope-specific T cells with a PD-1 axis binding antagonist and an RNA vaccine
|
CN113248611A
(zh)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
EP4106767A1
(en)
|
2020-02-21 |
2022-12-28 |
Université de Liège |
Depletion of ext1 expression and/or activity improves cellular production of biological entities
|
MX2022010217A
(es)
|
2020-02-21 |
2022-09-19 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma.
|
JP2023515478A
(ja)
|
2020-02-24 |
2023-04-13 |
アレクトル エルエルシー |
抗trem2抗体の使用方法
|
CN115803345A
(zh)
|
2020-03-05 |
2023-03-14 |
Umc乌得勒支控股有限公司 |
靶向蛋白质降解的膜泛素连接酶
|
TW202144410A
(zh)
|
2020-03-13 |
2021-12-01 |
美商建南德克公司 |
抗介白素-33抗體及其用途
|
JP2023520773A
(ja)
|
2020-03-27 |
2023-05-19 |
ノバルティス アーゲー |
増殖性疾患及び自己免疫疾患を治療するための二重特異性組合せ治療
|
JP2023519962A
(ja)
|
2020-03-31 |
2023-05-15 |
アレクトル エルエルシー |
抗mertk抗体及びその使用方法
|
WO2021203030A2
(en)
|
2020-04-03 |
2021-10-07 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
KR20220164787A
(ko)
|
2020-04-06 |
2022-12-13 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
암 및 감염의 치료를 위한 NKp46에 대한 항체 및 이의 작제물
|
CA3168954A1
(en)
|
2020-04-09 |
2021-10-14 |
Stefan Engelhardt |
Targeted delivery of an inhibitor of mir-21 to macrophages for the treatment of pulmonary fibrosis
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
JP2023522109A
(ja)
|
2020-04-21 |
2023-05-26 |
ウニベルシテ カソリーク デ ルーベン |
脾臓障害の防止及び/又は処置のためのアルファ-2アドレナリン受容体アゴニスト
|
EP4138803A1
(en)
|
2020-04-21 |
2023-03-01 |
Université catholique de Louvain |
Alpha-2 adrenergic receptor agonists for the treatment of cancer
|
EP4139449A1
(en)
|
2020-04-22 |
2023-03-01 |
Fabmid |
Methods for circularizing linear double stranded nucleic acids
|
AU2021258194A1
(en)
|
2020-04-22 |
2022-11-24 |
Indapta Therapeutics, Inc. |
Natural killer (NK) cell compositions and methods for generating same
|
AU2021262744A1
(en)
|
2020-04-27 |
2022-10-06 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
WO2021222533A1
(en)
|
2020-04-30 |
2021-11-04 |
Procisedx Inc. |
Methods of detecting antibodies to sars-cov-2
|
CN115812077A
(zh)
|
2020-05-08 |
2023-03-17 |
高山免疫科学股份有限公司 |
April和baff抑制性免疫调节蛋白及其使用方法
|
EP4149558A1
(en)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
GB202007312D0
(en)
|
2020-05-18 |
2020-07-01 |
Synthetic Vac Ltd |
Mimotope peptides of the spike protein from the sars-cov-2 virus
|
EP4155405A1
(en)
|
2020-05-22 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity
|
GB202008651D0
(en)
|
2020-06-09 |
2020-07-22 |
Univ Newcastle |
Method of identifying complement modulators
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
|
JP2023532431A
(ja)
|
2020-06-18 |
2023-07-28 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
標的-e3リガーゼの有効な組合せのスクリーニング法
|
JP2023530499A
(ja)
|
2020-06-22 |
2023-07-18 |
モルフォシス・アーゲー |
抗CD19抗体及びSIRPα-CD47自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法
|
TW202214683A
(zh)
|
2020-07-09 |
2022-04-16 |
大陸商北京凱因科技股份有限公司 |
結合b型肝炎病毒表面抗原的抗體及其應用
|
TW202216761A
(zh)
|
2020-07-16 |
2022-05-01 |
瑞士商諾華公司 |
抗β細胞素抗體、其片段及多特異性結合分子
|
KR20230043916A
(ko)
|
2020-07-23 |
2023-03-31 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
골수증식성 신생물의 새로운 치료학적 표적으로서 s100 단백질
|
FR3112939B1
(fr)
|
2020-07-31 |
2024-01-05 |
Univ Montpellier |
Produit universel de thérapie cellulaire et son utilisation
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
WO2022035793A1
(en)
|
2020-08-10 |
2022-02-17 |
Precision Biosciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
JP2023537396A
(ja)
|
2020-08-12 |
2023-08-31 |
ビオンド バイオロジクス リミテッド |
Ilt2に対する抗体およびその使用
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
CN114106173A
(zh)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
抗ox40抗体、其药物组合物及应用
|
FR3114160A1
(fr)
|
2020-09-11 |
2022-03-18 |
Dyameo |
Rapporteur fluorescent et son utilisation pour la détection de molécules cibles
|
AU2021339953A1
(en)
|
2020-09-11 |
2023-05-18 |
Medimmune Limited |
Therapeutic b7-h4 binding molecules
|
KR20230066095A
(ko)
|
2020-09-12 |
2023-05-12 |
메디뮨 리미티드 |
항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법
|
EP4214244A1
(en)
|
2020-09-21 |
2023-07-26 |
Genentech, Inc. |
Purification of multispecific antibodies
|
CA3189473A1
(en)
|
2020-09-24 |
2022-03-31 |
Andreas Bultmann |
Novel human antibodies binding to human cd3 epsilon
|
EP4217003A1
(en)
|
2020-09-24 |
2023-08-02 |
Genentech, Inc. |
Polysorbate mixtures having modified fatty acid ester distribution
|
JP2023548034A
(ja)
|
2020-10-22 |
2023-11-15 |
ヤンセン バイオテツク,インコーポレーテツド |
デルタ様リガンド3(dll3)抗原結合ドメインを含むタンパク質及びその使用
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
US20230372319A1
(en)
|
2020-11-02 |
2023-11-23 |
Ares Trading S.A. |
Combination Treatment of Cancer
|
EP4237001A1
(en)
|
2020-11-02 |
2023-09-06 |
Ares Trading S.A. |
Combination treatment of cancer
|
AU2021376354A1
(en)
|
2020-11-04 |
2023-06-22 |
Myeloid Therapeutics, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|
WO2022097090A1
(en)
|
2020-11-05 |
2022-05-12 |
Novartis Ag |
Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
|
US20240002509A1
(en)
|
2020-11-06 |
2024-01-04 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
CN116390933A
(zh)
|
2020-11-06 |
2023-07-04 |
诺华股份有限公司 |
治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法
|
CA3200974A1
(en)
|
2020-11-08 |
2022-05-12 |
Seagen Inc. |
Combination therapy
|
CR20230283A
(es)
|
2020-11-24 |
2023-07-27 |
Novartis Ag |
Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
|
US20240101681A1
(en)
|
2020-12-02 |
2024-03-28 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
KR20230131464A
(ko)
|
2020-12-04 |
2023-09-13 |
모르포시스 아게 |
항-cd19 병용 요법
|
EP4255925A1
(en)
|
2020-12-07 |
2023-10-11 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
CA3200847A1
(en)
|
2020-12-07 |
2022-06-16 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
WO2022125710A1
(en)
|
2020-12-09 |
2022-06-16 |
GHP Solutions, LLC |
Methods of detecting papp-a and related methods for gestational age assessment
|
EP4259661A1
(en)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
BR112023014418A2
(pt)
|
2021-01-20 |
2023-10-31 |
Oncoresponse Inc |
Anticorpos imunomoduladores e usos dos mesmos
|
CA3206413A1
(en)
|
2021-02-11 |
2022-08-18 |
Pinchas TSUKERMAN |
Antibodies against cd112r and uses thereof
|
TW202246324A
(zh)
|
2021-03-01 |
2022-12-01 |
美商艾希利歐發展股份有限公司 |
用於治療癌症的經掩蔽之ctla4及pd1/pdl1抗體之組合
|
EP4301467A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
JP2024508157A
(ja)
|
2021-03-04 |
2024-02-22 |
センター ナショナル デ ラ レシェルシェ サイエンティフィーク |
炎症、線維症及び肺疾患を治療するためのペリオスチン抗体の使用
|
IL305758A
(en)
|
2021-03-10 |
2023-11-01 |
Immunowake Inc |
Immunomodulatory compounds and their uses
|
KR20230156373A
(ko)
|
2021-03-15 |
2023-11-14 |
제넨테크, 인크. |
루푸스 신염의 치료 조성물 및 치료 방법
|
US20220306754A1
(en)
|
2021-03-18 |
2022-09-29 |
Medimmune Limited |
Therapeutic binding molecules
|
US20240174746A1
(en)
|
2021-03-18 |
2024-05-30 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
EP4314063A1
(en)
|
2021-03-23 |
2024-02-07 |
Alector LLC |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
WO2022201122A1
(en)
|
2021-03-26 |
2022-09-29 |
Janssen Biotech, Inc. |
Humanized antibodies against paired helical filament tau and uses thereof
|
KR20230165911A
(ko)
|
2021-04-09 |
2023-12-05 |
씨젠 인크. |
항-tigit 항체를 사용한 암의 치료 방법
|
AU2022258829A1
(en)
|
2021-04-16 |
2023-10-26 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
EP4326288A1
(en)
|
2021-04-21 |
2024-02-28 |
Indapta Therapeutics, Inc. |
Methods of treatment and dosing of natural killer cell compositions
|
EP4334355A1
(en)
|
2021-05-03 |
2024-03-13 |
UCB Biopharma SRL |
Antibodies
|
CN117222435A
(zh)
|
2021-05-03 |
2023-12-12 |
默克专利有限公司 |
HER2靶向Fc抗原结合片段-药物缀合物
|
CA3216795A1
(en)
|
2021-05-07 |
2022-11-10 |
Alpine Immune Sciences, Inc. |
Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
|
WO2022241057A1
(en)
|
2021-05-12 |
2022-11-17 |
Applied Biomedical Science Institute |
Binding polypeptides against sars cov-2 and uses thereof
|
WO2022242710A1
(zh)
|
2021-05-19 |
2022-11-24 |
上海诗健生物科技有限公司 |
一种特异性识别baff-r的嵌合抗原受体分子及其应用
|
EP4346905A1
(en)
|
2021-05-25 |
2024-04-10 |
Merck Patent GmbH |
Egfr targeting fc antigen binding fragment-drug conjugates
|
JP2024520764A
(ja)
|
2021-06-07 |
2024-05-24 |
アレス トレーディング ソシエテ アノニム |
癌の組み合わせ処置
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
WO2022266221A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Monovalent anti-mertk antibodies and methods of use thereof
|
WO2022263057A1
(en)
|
2021-06-18 |
2022-12-22 |
Advancecor Gmbh |
Use of a pharmaceutical composition
|
CA3225985A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
CA3227537A1
(en)
|
2021-07-27 |
2023-02-02 |
Morphosys Ag |
Combinations of antigen binding molecules
|
CN118076633A
(zh)
|
2021-07-29 |
2024-05-24 |
法国国家健康与医学研究院 |
人源化抗-人βig-h3蛋白及其用途
|
CN117897409A
(zh)
|
2021-08-13 |
2024-04-16 |
基因泰克公司 |
抗类胰蛋白酶抗体的给药
|
WO2023044321A1
(en)
|
2021-09-14 |
2023-03-23 |
Xilio Development, Inc. |
Cleavable linkers
|
WO2023064872A1
(en)
|
2021-10-14 |
2023-04-20 |
Precision Biosciences, Inc. |
Combinations of anti-bcma car t cells and gamma secretase inhibitors
|
WO2023064947A1
(en)
|
2021-10-15 |
2023-04-20 |
Regenxbio Inc. |
Antibodies and methods of using thereof
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
WO2023072958A1
(en)
|
2021-10-25 |
2023-05-04 |
Fabmid |
Methods for circularizing linear double stranded nucleic acids and the products thereof
|
AU2022378899A1
(en)
|
2021-10-27 |
2024-03-07 |
Granite Bio Ag |
Antibodies targeting ccr2
|
TW202325345A
(zh)
|
2021-10-27 |
2023-07-01 |
美商建南德克公司 |
約束性複合劑之合成
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
WO2023117987A1
(en)
|
2021-12-21 |
2023-06-29 |
Universität Zürich |
Adenoviral vectors
|
WO2023122665A1
(en)
|
2021-12-22 |
2023-06-29 |
Genentech, Inc. |
Clinical formulations of anti-tigit antibodies
|
WO2023122796A1
(en)
|
2021-12-23 |
2023-06-29 |
The Broad Institute, Inc. |
Parallel antibody engineering compositions and methods
|
WO2023148707A1
(en)
|
2022-02-07 |
2023-08-10 |
Yeda Research And Development Co. Ltd. |
Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
WO2023156625A1
(en)
|
2022-02-18 |
2023-08-24 |
Adivo Gmbh |
Feline antibody library
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
GB202202569D0
(en)
|
2022-02-24 |
2022-04-13 |
Amlo Biosciences Ltd |
Biomarkers for disease progression and/or recurrence in squamous cell carcinoma
|
US20230365641A1
(en)
|
2022-02-28 |
2023-11-16 |
Xilio Development, Inc. |
Targeted cytokines and methods of use thereof
|
WO2023164286A1
(en)
|
2022-02-28 |
2023-08-31 |
Xilio Development, Inc. |
Engineered cd122 compositions and methods thereof
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023170291A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
WO2023170296A1
(en)
|
2022-03-11 |
2023-09-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Nucleic acid system to specifically reprogram b and t cells and uses thereof
|
TW202345899A
(zh)
|
2022-03-11 |
2023-12-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(三)
|
TW202346355A
(zh)
|
2022-03-11 |
2023-12-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(二)
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
WO2023180346A1
(en)
|
2022-03-22 |
2023-09-28 |
Morphosys Ag |
Deimmunized antibodies specific for cd3
|
WO2023180527A1
(en)
|
2022-03-25 |
2023-09-28 |
Universität Zürich |
Adenoviral mediated targeting of activated immune cells
|
WO2023187657A1
(en)
|
2022-03-30 |
2023-10-05 |
Novartis Ag |
Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
|
US20230364020A1
(en)
|
2022-04-01 |
2023-11-16 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
TW202340259A
(zh)
|
2022-04-14 |
2023-10-16 |
瑞士商諾華公司 |
抗cd19藥劑之劑量方案及其用途
|
WO2023209716A1
(en)
|
2022-04-25 |
2023-11-02 |
Biond Biologics Ltd. |
Anti-ilt3 antibodies and use thereof
|
EP4269432A1
(en)
|
2022-04-26 |
2023-11-01 |
Universite de Rouen Normandie |
Production of therapeutic antibodies by the microalgae phaeodactylum tricornutum
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024008910A1
(en)
|
2022-07-07 |
2024-01-11 |
Cimeio Therapeutics Ag |
Antibodies targeting cd117
|
WO2024016003A2
(en)
|
2022-07-14 |
2024-01-18 |
The Broad Institute, Inc. |
Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
|
US20240141007A1
(en)
|
2022-07-15 |
2024-05-02 |
Xilio Development, Inc. |
Engineered cleavable carriers and methods of use thereof
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
US20240092859A1
(en)
|
2022-08-18 |
2024-03-21 |
Immunocore Ltd |
T cell receptors and fusion proteins thereof
|
WO2024047114A1
(en)
|
2022-08-31 |
2024-03-07 |
Universität Zürich |
Adenoviral-based in situ delivery of bispecific t cell engagers
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
WO2024077018A2
(en)
|
2022-10-04 |
2024-04-11 |
Alpine Immune Sciences, Inc. |
Methods and uses of taci-fc fusion immunomodulatory protein
|
WO2024074649A1
(en)
|
2022-10-05 |
2024-04-11 |
Alcea Therapeutics, Inc. |
Notch4 antibodies, compositions, and methods for treating airway inflammation
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024074706A1
(en)
|
2022-10-07 |
2024-04-11 |
Universität Zürich |
Paracrine adenoviral delivery of biomolecules
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
WO2024099990A1
(en)
|
2022-11-07 |
2024-05-16 |
Leibniz-Institut Für Immuntherapie (Lit) |
TGF-ß SWITCH RECEPTOR CAR T CELLS
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100663A1
(en)
|
2022-11-10 |
2024-05-16 |
Famewave Ltd. |
Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
|
WO2024108178A1
(en)
|
2022-11-18 |
2024-05-23 |
Genentech, Inc. |
Signal amplification and multiplexing using mass tags for ia-lc-ms/ms based assays
|